

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Determinants of clinical complexity in hospitalised cirrhotic patients

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-077576
Article Type:	Original research
Date Submitted by the Author:	09-Jul-2023
Complete List of Authors:	Lenti, Marco; Università degli Studi di Pavia, First Department of Internal Medicine Ballesio, Alessia; University of Pavia, Department of Internal Medicine and Medical Therapeutics; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Croce, Gabriele; University of Pavia, Department of Internal Medicine and Medical Therapeutics; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Brera, Alice Silvia; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Padovini, Lucia; University of Pavia, Department of Internal Medicine and Medical Therapeutics; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Bertolino, Giampiera; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Di Sabatino, Antonio; Università degli Studi di Pavia, First Department of Medicine Klersy, Catherine; Fondazione IRCCS Policlinico San Matteo, Service of Clinical Epidemiology & Biometry, Research Department Corazza, Gino; University of Pavia, Department of Internal Medicine and Medical Therapeutics; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine
Keywords:	Aging, Adult gastroenterology < GASTROENTEROLOGY, Hepatobiliary disease < GASTROENTEROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Determinants of clinical complexity in hospitalised cirrhotic patients

Running head: liver cirrhosis and co-multimorbidity

Marco Vincenzo Lenti,^{1,2} MD, Alessia Ballesio,^{1,2} MD, Gabriele Croce,^{1,2} MD, Alice Silvia Brera,² BSc, Lucia Padovini,^{1,2} MD, Giampiera Bertolino,² MD, Antonio Di Sabatino,^{1,2} MD, Catherine Klersy,³ MD, Gino Roberto Corazza,^{1,2} MD

¹Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy; ²First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; ³Clinical Epidemiology & Biometry, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.

Electronic word count: 2198

Corresponding author details: Prof. Gino Roberto Corazza, Emeritus Professor of Internal Medicine, Clinica Medica I, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy. Tel: 0039 0382 502973-2954; Fax: 0039 0382 502618; E-mail: gr.corazza@smatteo.pv.it

Abstract

Objectives: There are no data regarding the prevalence of comorbidity (i.e., additional conditions in reference to an index disease) and multimorbidity (i.e., co-occurrence of multiple diseases in which no one holds priority) in patients with liver cirrhosis. We sought to determine the rate and differences between co-multimorbidity depending on the aetiology of cirrhosis. **Design:** This is a sub-analysis of the SMAC study (prospective study, internal medicine ward). We have analysed demographic and clinical characteristics of patients with liver cirrhosis depending on the aetiology - alcoholic, infectious, and non-alcoholic fatty liver disease (NAFLD). The prevalence and risk factors for comorbidity and multimorbidity were assessed. **Setting:** Single-centre study conducted in a tertiary referral, academic, internal medicine ward in northern Italy. **Participants:** Data from 1451 patients previously enrolled in the SMAC study were assessed; only those with liver cirrhosis were eventually included. **Results:** Of the 1451 patients, 187 (median age 78 years, IQR 66-84; 88 females) had liver cirrhosis. Patients with cirrhosis displayed higher Cumulative Illness Rating Scale (CIRS) comorbidity ($p=0.003$) and severity ($p<0.001$) indexes, and lower educational level ($p=0.002$). Patients with alcohol cirrhosis were significantly younger than patients with cirrhosis of other aetiologies ($p<0.001$) and more commonly males. Comorbidity was more prevalent in patients with alcohol cirrhosis and multimorbidity more prevalent in viral and NAFLD cirrhosis ($p=0.015$). In a multivariable model for factors associated with multimorbidity, a CIRS comorbidity index >3 (OR 2.81, $p=0.024$) and admission related to cirrhosis (OR 0.19, $p=0.002$) were the only significant associations. **Conclusions:** Patients with liver cirrhosis had a higher disease burden and a lower educational level compared to other patients. The different patterns of co- and multimorbidity might translate into different pathways of care.

Keywords: ageing; alcohol; chronic liver disease; multimorbidity.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- We collected prospective data from patients with liver cirrhosis admitted to an internal medicine ward and we have described for the first time the rates of, and factors associated with, comorbidity and multimorbidity in this population.
- We have also divided patients according to the liver aetiology, finding that those with alcohol cirrhosis were significantly younger than patients with infectious or non-alcoholic liver disease cirrhosis and more commonly males.
- The sample size was rather small, especially for some cirrhosis aetiologies, so we had to exclude some patients from our analysis.
- Generalisability of our results is limited to the internal medicine setting, and cannot be applied to other specialty settings, nor to the primary care.

Introduction

Clinical complexity (CC) is one of the most challenging issues of modern medicine, especially in internal medicine, and it originates from the interaction between the patient's own factors and other external, but contextual, factors.¹⁻² Its fundamental attributes are represented by interconnectedness, non-linearity, context-sensitivity, and unpredictability.³⁻

⁵ Among the most important determinants of CC, the association of multiple chronic conditions (MCC) within the same patient is certainly one of the most relevant, and for some years MCC and CC have been identified in each other. However, subsequent studies have demonstrated that CC is something more and different compared to the mere disease associations, and it includes both biological (i.e., ageing, MCC, frailty, mental impairment, malnutrition, dependency) and non-biological (i.e., socioeconomic, cultural, environmental, behavioural) variables.^{3,6,7}

Among various end-stage organ failure, liver cirrhosis is an example of CC and of systemic condition.⁸ To mention a few disease-related manifestations, ascites, hepatic encephalopathy, cell blood count alterations, coagulopathy, and gastrointestinal bleeding, all have a negative impact on both physical and mental functioning.⁹ Additionally, patients with cirrhosis frequently have MCC,¹⁰⁻¹² although their impact on prognosis remains unclear.¹² Besides its biological complexity, the impact of socioeconomic factors, i.e., education, marital and employment status, household income, is an additional detrimental factor the effects of which appear to vary according to disease aetiology,^{13,14} and to have a relevant impact on survival and overall patients' management.^{13,15} In particular, different networks and trajectories of disease association might be noticed according to the specific aetiology of cirrhosis, such as chronic viral hepatitis (HBV-, HCV-related), alcoholic liver disease, autoimmune liver disease, and non-alcoholic fatty liver disease (NAFLD).¹⁶

On these bases, we sought to analyse a population of cirrhotic patients admitted to an internal medicine ward, in order to highlight whether any difference exists in the rate of MCC

1
2
3 and other determinants of CC in relation to patients' characteristics and to the specific
4
5 aetiology of liver cirrhosis.
6
7
8

9 10 **Methods**

11
12 For the purpose of this paper, data from the San MATteo Complexity (SMAC) study were
13
14 used. The SMAC study is a large ongoing prospective research project regarding clinical
15
16 complexity (NCT03439410) conducted at our Institution.¹⁷⁻²⁰ Specifically, adult patients
17
18 (age >18 years) admitted to our internal medicine ward, regardless of the cause, were
19
20 consecutively enrolled from November 2017 to November 2019. Patients with a prognosis
21
22 <48 hours and denial of informed consent were the only exclusion criteria. The telephone
23
24 follow-up, scheduled for up to five years, is still ongoing.
25
26

27
28 In the present study, which is a sub-analysis of the SMAC study, among all enrolled patients
29
30 (n. 1451), we selected those with a clinical diagnosis of liver cirrhosis according to the
31
32 International Classification of Diseases (ICD) 9 codes (i.e., 571, 571.2, 571.5, 571.6, 571.4,
33
34 571.40, 571.41, 571.49, 571.8, 571.9). Also, the discharge letter of each cirrhotic patient
35
36 was reviewed for confirming the aetiology of the disease. Applying these criteria, 187
37
38 cirrhotic patients (median age 78 years, IQR 66-84; 88 females) were identified.
39
40

41
42 Among all causes of cirrhosis, we categorised patients as having alcohol, viral (either by
43
44 HBV and/or HCV infection), or NAFLD cirrhosis. For comparison among liver aetiologies,
45
46 we excluded patients with undetermined or rare causes of cirrhosis, namely primary biliary
47
48 cholangitis (n=1), cryptogenic or undetermined cirrhosis (n=12), Budd-Chiari syndrome
49
50 (n=1), and polycystic liver disease with advanced liver failure (n=1). In the "undetermined"
51
52 aetiology group, we have also included cases in which a single aetiology, among many,
53
54 was not possible to ascertain. In case of multiple aetiologies, we selected either the leading
55
56 or the more lasting cause of liver injury.
57
58
59
60

1
2
3 Considering its clinical features and the progressive disease course, liver cirrhosis could
4 ideally represent a model of comorbidity or multimorbidity, both encompassing the concept
5 of MCC. In this regard, recently standardised definitions for comorbidity and multimorbidity
6 have been introduced to distinguish patients in the context of MCC.²⁰⁻²² In
7 particular, comorbidity indicates the combined effects of additional conditions in reference
8 to an index disease under study, whereas multimorbidity indicates the mere co-occurrence
9 of multiple diseases within the same individual, in which no single disease holds priority.
10 Accordingly, specific novel medical subject heading (MeSH) definitions have been released
11 for indexing purposes.²¹ Following these definitions, all our patients have been categorised
12 as having either comorbidity or multimorbidity. For example, patients having only
13 complications of liver cirrhosis (namely cirrhosis decompensation, gastrointestinal
14 bleeding, hepatic encephalopathy, ascites) have been categorised as being comorbid,
15 while patients with association with other conditions have been categorised as having
16 multimorbidity.

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35 As a primary aim, we looked at possible determinants of CC in cirrhotic patients, compared
36 to the whole SMAC cohort, as well as the overall rates of co- or multimorbidity. As a
37 secondary aim, we compared the rate of comorbidity and multimorbidity according to the
38 aetiology of liver cirrhosis, as well as other potential determinants of CC, including sex,
39 BMI, schooling, income, Cumulative Illness Rating Scale (CIRS) comorbidity e severity
40 index, resilience, Edmonton Frail Scale, Barthel index, Short Blessed Test (SBT), length of
41 stay (LOS). The causes of admission to hospital were categorised as either related or
42 unrelated to liver cirrhosis and were included in the multivariable analysis.

43
44
45
46
47
48
49
50
51
52
53 Finally, we sought to determine the factors affecting the risk of having multimorbidity
54 according to the aetiology.

55
56
57
58 All patients provided written informed consent prior to study enrolment and the study
59 protocol was approved by the local Ethics Committee (San Matteo Hospital Foundation; 3
60

1
2
3 July 2017, Protocol number 2017/0019414). The consent for publication of data was also
4
5 obtained by all patients. This research was performed in accordance with the Declaration of
6
7 Helsinki. There were no uneducated participants in this study. The full dataset of the study
8
9 cannot be shared publicly at this stage, since the SMAC study is still ongoing. Additional
10
11 data can be shared upon request to the authors.
12
13
14
15
16

17 Statistical analysis

18
19 Continuous data were described with the median and interquartile range (IQR) and
20
21 compared with the Mann Whitney U test or the Kruskal Wallis test. Categorical data were
22
23 reported as counts and percent and compared with the Fisher exact test. Based on clinical
24
25 considerations we chose a priori a series of candidate variables, which were considered
26
27 the most relevant patient clinical characteristics according to the aetiology of cirrhosis.
28
29 These were checked for collinearity and were included in a logistic multivariable model.
30
31 The area under the model ROC curve was computed as a measure of model performance.
32
33 The model calibration was assessed graphically using the calibration plot and the
34
35 corresponding statistic test was computed. The software Stata 17 (StataCorp, College
36
37 Station, TX, USA) was used for all computations. The study follows the STROBE
38
39 recommendations for quality assurance.
40
41
42
43
44
45

46 Patient and public involvement

47
48 Patients or the public were not involved in the design, or conduct, or reporting, or
49
50 dissemination plans of our research.
51
52
53
54

55 **Results**

56
57 Table 1 reports the baseline characteristics of the entire cohort of 187 cirrhotic patients
58
59 compared to the other 1264 patients included in the SMAC study. Patients with cirrhosis
60

1
2
3 displayed higher CIRS comorbidity ($p=0.003$) and severity ($p<0.001$) indexes, higher rate of
4 comorbidity ($p=0.001$), lower educational level ($p=0.002$), and higher length of stay
5 ($p=0.025$). No other significantly different results were noticed for sex, nutritional status,
6 frailty, dependency, cognitive impairment, income, and living alone. Thereafter, 15 cirrhotic
7 patients were excluded, as having rarer or undetermined aetiologies, and the subsequent
8 analyses will therefore focus on 172 patients.
9

10
11 Table 2 reports the main demographic and clinical characteristics of patients with liver
12 cirrhosis according to their aetiologies. Notably, we found that patients with alcohol cirrhosis
13 were significantly younger and more commonly males than patients with cirrhosis of other
14 aetiologies ($p<0.001$). As expected, BMI was significantly higher in patients with NAFLD
15 cirrhosis ($p<0.001$). No differences among groups were noticed in terms of CIRS comorbidity
16 and severity indexes, frailty, dependency, cognitive impairment, living alone, schooling, and
17 length of stay. Regarding the rates of comorbidity and multimorbidity, we found a statically
18 significant difference among the three groups ($p=0.015$), being comorbidity more prevalent
19 in patients with alcohol aetiology and multimorbidity more prevalent in viral and NAFLD
20 cirrhosis.
21

22
23 Finally, in a multivariable model looking at factors affecting the risk of having multimorbidity
24 (Table 3), we found that a CIRS comorbidity index >3 (OR 2.81, $p=0.024$) was significantly
25 correlated, while the admission related to cirrhosis (OR 0.19, $p=0.002$) was significantly and
26 inversely correlated with this outcome.
27
28
29
30
31
32
33
34
35
36
37
38
39

40 41 42 43 44 45 46 47 48 49 50 51 **Discussion**

52
53 Patients with liver cirrhosis, due to their systemic clinical involvement,^{8,9} the frequent
54 association with MCC,¹⁰⁻¹² polypharmacy,¹¹ and the possible interference of extra-biological
55 factors,^{11,13,14} certainly represent a prototype of CC. Concerning clustering of MCC, the
56
57
58
59
60

1
2
3 recent possibility to label patients as having co- or multimorbidity²⁰⁻²² could potentially
4 translate into a different clinical management.^{23,24}
5
6

7 We herein found some important differences regarding baseline clinical characteristics of
8 cirrhotic patients compared to the whole cohort of patients hospitalised in an academic,
9 internal medicine ward. In particular, cirrhotic patients had an even greater CIRS indexes
10 (comorbidity and severity) and higher rates of co- and multimorbidity, as well as a lower
11 educational level, despite being similarly frail and dependent, and had a similarly impaired
12 cognitive function. These latter results were not unexpected, considering that our controls
13 were similarly old (median age 80 years vs 78) and hospitalised. In a similar large,
14 prospective, and multicentric study, although including only patients greater than 65 years
15 old, enrolled in internal medicine and geriatric wards, among 6193 patients, liver cirrhosis
16 was found in 315 (5%); of these, 43% were multimorbid, 44% had cognitive impairment, and
17 51% were disabled.²⁵
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 The present study is the first in which a distinction between comorbidity and multimorbidity
34 in a population of hospitalised patients with a specific chronic disease was performed.
35 Indeed, previous studies have analysed the presence of MCC in patients with liver
36 disease,¹⁰⁻¹² but the term “comorbidity” has been used with a different meaning, outside the
37 current MeSH definition.²¹ In these studies,¹⁰⁻¹² it was evident that patients with cirrhosis
38 suffered from many other disorders, but they have not been identified as either a
39 consequence of cirrhosis itself or its aetiologic factor (i.e., comorbidities) or as separate
40 entities (i.e., multimorbidity).
41
42
43
44
45
46
47
48
49

50 Regarding differences among cirrhosis aetiologies in our study, we found that viral (median
51 age 81 years, IQR 77-85) and NAFLD (median age 78 years, IQR 65-82) cirrhotic patients
52 were significantly older than alcohol cirrhosis patients (median age 65 years, IQR 56-79),
53 as already demonstrated in other studies.^{10,26,27} This translates into a higher rate of
54 multimorbidity -that we actually found- possibly due to the stochastic accumulation of
55
56
57
58
59
60

1
2
3 different disorders with advanced age. Conversely, in patients with alcohol cirrhosis, the
4 higher rate of comorbidity could be interpreted as a direct consequence of alcohol abuse
5 which is a strong and well-known risk factor for multiple organ involvement, often underlying
6 a common psychopathological basis.²⁸ Additionally, in the alcohol cirrhosis group, we found
7 a clear male predominance, while in the other groups there was not a prominent difference
8 with regard to biological sex, and this is consistent with previous reports.^{27,29} Of note,
9 although a higher prevalence of alcoholic cirrhosis in male patients is expected, the gap in
10 alcohol consumption between men and women has been progressively narrowing over the
11 last years.³⁰

12
13 Admission related to cirrhosis was found to be inversely related to the presence of
14 multimorbidity, while CIRS was directly related to multimorbidity. These correlations
15 represent a counterproof of the validity of the classification applied for categorizing patients
16 as having either co- or multimorbidity. For example, a patient with cirrhosis and many other
17 randomly associated MCC (multimorbid) would be more likely to be admitted to hospital due
18 to one of these many MCC compared to a patient with cirrhosis and its classical
19 comorbidities, such as ascites, gastrointestinal bleeding, or encephalopathy (comorbid). It
20 is not surprising that, according to a recent expert consensus, the evaluation of
21 socioeconomic factors, educational status, and comorbid psychiatric illness should all be
22 taken into account by a multidisciplinary team in alcohol cirrhosis patients.²⁸ In fact, a low
23 educational level was found to be common in our alcohol cirrhosis patients, and
24 interventions aimed at improving one's knowledge of the disease may translate into a
25 therapeutic advantage.

26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 **Limitations**

57 We are aware that our study has some limitations that should be mentioned. The sample
58 size was rather small, especially for some cirrhosis aetiologies (e.g., autoimmune liver
59
60

1
2
3 disease), so we had to exclude these patients from our analysis. Hence, a wider
4
5 multivariable analysis could not be made. Even if our data should be considered as
6
7 preliminary in this field, a distinction between co- and multimorbidity could potentially aid
8
9 decision-making in cirrhotic patients, in whom a prioritisation of the clinical problems to be
10
11 solved is mandatory. Also, our data should be interpreted in the light of the specific setting
12
13 of enrolment, in which patients admitted are usually older than in others. Nevertheless, this
14
15 study had some strengths, including a prospective collection of data, not administrative
16
17 based, but collected during the hospitalisation by a dedicated and qualified staff of
18
19 healthcare professionals who had been instructed before study commencement.¹⁸
20
21
22
23
24
25

26 **Conclusion**

27
28 To conclude, we have performed the first study focusing on the distinction of comorbidity
29
30 and multimorbidity in a cohort of patients with a specific chronic condition. We found that
31
32 patients with alcoholic cirrhosis had a high comorbidity rate, while the other aetiologies -viral
33
34 and NAFLD- were mostly multimorbid due to ageing. How these characteristics may
35
36 translate into distinct and personalised clinical management should be further investigated.
37
38
39
40
41

42 **Data availability statement**

43
44 The full dataset of the study cannot be shared publicly at this stage, since the SMAC study
45
46 is still ongoing. Additional data can be shared upon request to the authors (please contact
47
48 Prof. Gino Roberto Corazza at the email address provided).
49
50
51

52 **Ethics statements**

53 **Patient consent for publication**

54
55
56 Acquired by all patients before enrolment.
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Ethics approval

The study protocol was approved by the local Ethics Committee (San Matteo Hospital Foundation; 3 July 2017, Protocol number 2017/0019414). This research was performed in accordance with the Declaration of Helsinki. There were no uneducated participants in this study.

Competing interests

The authors report no conflict of interest.

Funding

This research is part of a project for the study of clinical complexity (SMAC study) funded by San Matteo Hospital Foundation - Italian Ministry of Health (Progetto di Ricerca Corrente 2017; award number not applicable). The funding source had no role in the design, execution, analyses, and interpretation of the data.

Authors contributions

All authors participated in the drafting of the manuscript or critical revision of the manuscript for important intellectual content and provided approval of the final submitted version. Individual contributions are as follow: GRC designed and coordinated the study; MVL and AB drafted the manuscript; all authors organised data collection conducted the study and/or enrolled patients; CK designed and performed statistical analysis, interpreted data, and revised the manuscript; GRC made the final critical revision for important intellectual content. All authors approved the final version of the paper.

Acknowledgements

None.

1
2
3
4
5 **Abbreviations:** CIRS, Cumulative Illness Rating Scale; IQR, interquartile range; LOS,
6 length of stay; MCC, multiple chronic conditions; MeSH, medical subject heading; NAFLD,
7 non-alcoholic fatty liver disease; SBT, Short Blessed Test; SMAC, San MAteeo Complexity.
8
9
10
11
12
13

14 **References**

- 15
16
17
18
19 1. Safford MM, Allison JJ, Kiefe CI. Patient complexity: more than comorbidity. the
20 vector model of complexity. *J Gen Intern Med.* 2007;3:382-390.
21
22
- 23 2. Turner BJ, Cuttler L. The complexity of measuring clinical complexity. *Ann Intern*
24 *Med.* 2011;155:851-852.
25
26
- 27 3. Corazza GR, Formagnana P, Lenti MV. Bringing complexity into clinical practice: An
28 internistic approach. *Eur J Intern Med.* 2019;61:9-14.
29
30
- 31 4. Goldenfeld N, Kadanoff LP. Simple lessons from complexity. *Science.* 1999;284:87-
32 89.
33
34
- 35 5. Plsek PE, Greenhalgh T. Complexity science: The challenge of complexity in health
36 care. *BMJ.* 2001;323:625-628.
37
38
- 39 6. Grant RW, Ashburner JM, Hong CS, Chang Y, Barry MJ, Atlas SJ. Defining patient
40 complexity from the primary care physician's perspective: a cohort study. *Ann Intern*
41 *Med.* 2011;155:797-804.
42
43
- 44 7. Hong CS, Atlas SJ, Ashburner JM, et al. Evaluating a model to predict primary care
45 physician-defined complexity in a large academic primary care practice-based
46 research network. *J Gen Intern Med.* 2015;30:1741-1747.
47
48
- 49 8. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. *Lancet.* 2014;383:1749-1761.
50
51
- 52 9. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of
53 survival in cirrhosis: a systematic review of 118 studies. *J Hepatol.* 2006;44:217-231.
54
55
56
57
58
59
60

10. Yang TW, Wang CC, Tsai MC, Wang YT, Tseng MH, Lin CC. Comorbidities and outcome of alcoholic and non-alcoholic liver cirrhosis in Taiwan: a population-based study. *Int J Environ Res Public Health*. 2020;17:2825.
11. Vaz J, Eriksson B, Strömberg U, Buchebner D, Midlöv P. Incidence, aetiology and related comorbidities of cirrhosis: a Swedish population-based cohort study. *BMC Gastroenterol*. 2020;20:84.
12. Jepsen P. Comorbidity in cirrhosis. *World J Gastroenterol*. 2014;20:7223-7230.
13. Jepsen P, Vilstrup H, Andersen PK, Sørensen HT. Socioeconomic status and survival of cirrhosis patients: a Danish nationwide cohort study. *BMC Gastroenterol*. 2009;9:35.
14. Roesch-Dietlen F, González-Santes M, Sánchez-Maza YJ, ET AL. Influence of socioeconomic and cultural factors in the aetiology of cirrhosis of the liver. *Rev Gastroenterol Mex*. 2021;86:28-35.
15. Vaz J, Strömberg U, Eriksson B, et al. Socioeconomic and marital status among liver cirrhosis patients and associations with mortality: a population-based cohort study in Sweden. *BMC Public Health* 2020. [Epub ahead of print]
16. Menche J, Sharma A, Kitsak M, et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. *Science* 2015;347:1257601.
17. Corazza GR, Klersy C, Formagnana P, Lenti MV, Padula D; Consensus Panel. A consensus for the development of a vector model to assess clinical complexity. *Intern Emerg Med*. 2017;12:1313-1318.
18. Lenti MV, Klersy C, Brera AS, et al. Reproducibility in the assessment of the components of a clinical complexity index. *J Gen Intern Med*. 2019;34:2316-2318.
19. Lenti MV, Klersy C, Brera AS, et al. Clinical complexity and hospital admissions in the December holiday period. *PLoS One*. 2020;15:e0234112.

- 1
2
3 20. Lenti MV, Klersy C, Brera AS, et al. Aging underlies heterogeneity between
4 comorbidity and multimorbidity frameworks. *Intern Emerg Med*. 2022 [Epub ahead of
5 print]
6
7
8
9
10 21. Tugwell P, Knottnerus JA. Multimorbidity and comorbidity are now separate MESH
11 headings. *J Clin Epidemiol*. 2019 [Epub ahead of print]
12
13
14 22. Nicholson K, Makovski TT, Griffith LE, Raina P, Stranges S, van den Akker M.
15 Multimorbidity and comorbidity revisited: refining the concepts for international health
16 research. *J Clin Epidemiol*. 2019;105:142-146.
17
18
19 23. Richardson WS, Doster LM. Comorbidity and multimorbidity need to be placed in the
20 context of a framework of risk, responsiveness, and vulnerability. *J Clin Epidemiol*.
21 2014;67:244-246.
22
23
24 24. Dekker J, Buurman BM, van der Leeden M. Exercise in people with comorbidity or
25 multimorbidity. *Health Psychol*. 2019;38:822-830.
26
27
28 25. De Vincentis A, Vespasiani-Gentilucci U, Costanzo L, et al; REPOSI Investigators.
29 The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of
30 the REPOSI registry. *Age Ageing*. 2021;50:498-504.
31
32
33 26. Dam Fialla A, Schaffalitzky de Muckadell OB, Touborg Lassen A. Incidence, aetiology
34 and mortality of cirrhosis: a population-based cohort study. *Scand J Gastroenterol*.
35 2012;47:702-709.
36
37
38 27. Sajja KC, Mohan DP, Rockey DC. Age and ethnicity in cirrhosis. *J Investig Med*.
39 2014;62:920-926.
40
41
42 28. Singal AK, Kwo P, Kwong A, et al. Research methodologies to address clinical unmet
43 needs and challenges in alcohol-associated liver disease. *Hepatology*. 2021 [Epub
44 ahead of print]
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 29. Wilsnack RW, Wilsnack SC, Kristjanson AF, Vogeltanz-Holm ND, Gmel G. Gender
4 and alcohol consumption: patterns from the multinational GENACIS project.
5
6
7
8 *Addiction*. 2009;104:1487-500.
9

10 30. Kezer CA, Simonetto DA, Shah VH. Sex differences in alcohol consumption and alcohol-
11 associated liver disease. *Mayo Clin Proc*. 2021;96:1006-1016.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1 **Table 1.** Baseline characteristics of the entire cohort of patients.
2

	Cirrhotic patients	*Other patients	p value
Total number of patients, n (%)	187 (12.9)	1264 (87.1)	
Age, median (IQR)	78.0 (66.0-84.0)	80.0 (70.0-86.0)	0.351
Sex, n (%)			0.071
M	99 (52.9)	579 (45.8)	
F	88 (47.1)	685 (54.2)	
CIRS comorbidity index, median (IQR)	4.0 (3.0-5.0)	4.0 (2.0-5.0)	0.003
CIRS severity index, median (IQR)	1.8 (1.6-2.0)	1.7 (1.5-1.9)	<0.001
Co- multimorbidity, n (%)			0.001
None	0 (0)	57 (4.6)	
Comorbidity	42 (22.7)	250 (20.3)	
Multimorbidity	143 (77.3)	927 (75.1)	
BMI, median (IQR)	25.2 (21.5-29.3)	24.2 (21.3-27.7)	0.056
Edmonton >5, n (%)			1.0
No	57 (30.5)	377 (30.5)	
Yes	130 (69.5)	857 (69.5)	
Barthel <60, n (%)			0.706
No	148 (79.1)	957 (77.5)	
Yes	39 (20.9)	278 (22.5)	
SBT >9, n (%)			1.0
No	88 (47.3)	580 (47.2)	
Yes	98 (52.7)	650 (52.8)	
Income <1000 €/mon, n (%)			0.814
No	96 (51.3)	644 (52.3)	
Yes	91 (48.7)	587 (47.7)	
Living alone, n (%)			0.514
No	148 (79.1)	948 (76.8)	
Yes	39 (20.9)	287 (23.2)	
Schooling <8, n (%)			0.023
No	73 (39.0)	592 (48.0)	
Yes	114 (61.0)	641 (52.0)	
LOS median (IQR)	14.0 (9.0-20.0)	15.0 (10.0-23.0)	0.025

3 *This includes all the other patients enrolled in the SMAC study, with the exception of cirrhotic patients, as explained in the text. Abbreviations: BMI, Body Mass Index; CIRS,
4 Cumulative Illness Rating Scale; SBT, Short Blessed Test; LOS, long of stay.

5
6

7 **Table 2.** Baseline characteristics of patients with cirrhosis according to the aetiology.

	Alcohol (I)	Viral (II)	NAFLD (III)	p-value
Total number of patients, n (%)	33 (19.2)	79 (45.9)	60 (34.9)	/
Age, median (IQR)	65 (56-79)	81 (77-85)	78 (65-82)	< 0.001 0.007 (II vs III) < 0.001 (II vs I) 0.005 (III vs I)
Sex, n (%)				0.008
Male	25 (75.8)	37 (46.8)	27 (45.0)	
Female	8 (24.2)	42 (53.2)	33 (55.0)	
CIRS comorbidity index, median (IQR)	4.0 (3.0-5.0)	4.0 (3.0- 5.0)	4.0 (3.0- 6.0)	0.314
CIRS severity index, median (IQR)	1.85 (1.62- 1.92)	1.85 (1.62- 2.0)	1.85 (1.69- 2.15)	0.423
Co-multimorbidity, n (%)				0.015
Comorbidity	13 (39.4)	15 (19.0)	8 (13.3)	
Multimorbidity	20 (60.6)	64 (81.0)	52 (86.7)	
BMI, median (IQR)	23.4 (21.5- 29.4)	23.5 (20.5- 26.6)	27.1 (23.7- 31.8)	<0.001 <0.001 (II vs III) 0.11 (II vs I) 0.02 (III vs I)
Edmonton >5, n (%)				0.604
No	11 (33.3)	20 (25.3)	19 (31.7)	
Yes	22 (66.7)	59 (74.7)	41 (68.3)	
Barthel <60				0.164
No	29 (87.9)	57 (72.1)	48 (80)	
Yes	4 (12.1)	22 (27.9)	12 (20)	
Income <1000 €/mon, n (%)				0.523
No	14 (42.4)	43 (54.4)	32 (53.3)	
Yes	19 (57.6)	36 (45.6)	28 (46.7)	
Living alone, n (%)				0.219
No	26 (78.8)	59 (74.7)	52 (86.7)	
Yes	7 (21.2)	20 (25.3)	8 (13.3)	
Schooling <8, n (%)				0.282
No	12 (36.4)	28 (35.4)	29 (48.3)	
Yes	21 (63.6)	51 (64.6)	31 (51.7)	
SBT >9, n (%)				0.102
No	20 (60.6)	31 (39.7)	31 (51.7)	
Yes	13 (39.4)	47 (60.3)	29 (48.3)	
LOS median (IQR)	12.0 (8.0-19.0)	14.0 (9.0- 19.0)	14.0 (10.0-21.5)	0.423

8 Abbreviations: BMI, Body Mass Index; CIRS, Cumulative Illness Rating Scale; SBT, Short Blessed Test; LOS, length of stay.

9

10 **Table 3.** Multivariable analysis for factors associated with multimorbidity.

	Odds ratio	95% CI	p-value
Sex			
Male	1.0 (base)		
Female	1.63	0.64-4.14	0.308
Aetiology of cirrhosis			
0.148			
Viral	1.0 (base)		
NAFLD	0.81	0.27-2.40	0.698
Alcohol	0.35	0.12-1.02	0.055
CIRS comorbidity index >3			
No	1.0 (base)		
Yes	2.81	1.14-6.93	0.024
Barthel <60			
No	1.0 (base)		
Yes	2.84	0.61- 13.29	0.186
Admission related to cirrhosis			
No	1.0 (base)		
Yes	0.19	0.07-0.54	0.002

12 Model χ^2 36.77, p-value<0.001; area under the ROC curve=0.81; calibration belt p=0.615, plot within 95%
 13 CI. Abbreviations: Cumulative Illness Rating Scale, CIRS; NAFLD, non-alcoholic fatty liver disease.

STROBE Statement—checklist of items that should be included in reports of observational studies
 Paper: Determinants of clinical complexity in hospitalized cirrhotic patients by Lenti MV et al.

	Item No.	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4-5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	4-6
Study size	10	Explain how the study size was arrived at	6

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Continued on next page

For peer review only

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	NA
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6-8
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6-8
		(b) Indicate number of participants with missing data for each variable of interest	6-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	6-8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	6-8
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6-8
		(b) Report category boundaries when continuous variables were categorized	6-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	8-10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	8-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	8-10
Generalisability	21	Discuss the generalisability (external validity) of the study results	8-10
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Comorbidity and multimorbidity in cirrhotic patients hospitalised in an internal medicine ward: a monocentric, cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-077576.R1
Article Type:	Original research
Date Submitted by the Author:	03-Feb-2024
Complete List of Authors:	Lenti, Marco; Università degli Studi di Pavia, First Department of Internal Medicine Ballesio, Alessia; University of Pavia, Department of Internal Medicine and Medical Therapeutics; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Croce, Gabriele; University of Pavia, Department of Internal Medicine and Medical Therapeutics; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Brera, Alice Silvia; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Padovini, Lucia; University of Pavia, Department of Internal Medicine and Medical Therapeutics; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Bertolino, Giampiera; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Di Sabatino, Antonio; Università degli Studi di Pavia, First Department of Medicine Klersy, Catherine; Fondazione IRCCS Policlinico San Matteo, Service of Clinical Epidemiology & Biometry, Research Department Corazza, Gino Roberto; Fondazione IRCCS Policlinico San Matteo, Department of Internal Medicine
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	General practice / Family practice
Keywords:	Aging, Adult gastroenterology < GASTROENTEROLOGY, Hepatobiliary disease < GASTROENTEROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 **Comorbidity and multimorbidity in cirrhotic patients hospitalised in an**
5
6 **internal medicine ward: a monocentric, cross-sectional study**
7
8

9 Running head: liver cirrhosis and co-multimorbidity
10

11
12 Marco Vincenzo Lenti,^{1,2} MD, Alessia Ballesio,^{1,2} MD, Gabriele Croce,^{1,2} MD, Alice Silvia
13 Brera,² BSc, Lucia Padovini,^{1,2} MD, Giampiera Bertolino,² MD, Antonio Di Sabatino,^{1,2} MD,
14 Catherine Klersy,³ MD, Gino Roberto Corazza,^{1,2} MD
15
16
17

18
19
20 ¹Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy;
21 ²First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia,
22 Italy; ³Clinical Epidemiology & Biometry, Fondazione IRCCS Policlinico San Matteo, Pavia,
23 Italy.
24
25
26
27
28
29

30 **Electronic word count:** 2602
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 **Corresponding author details:** Prof. Gino Roberto Corazza, Emeritus Professor of
56 Internal Medicine, Clinica Medica I, Fondazione IRCCS Policlinico San Matteo, Viale Golgi
57 19, 27100 Pavia, Italy. Tel: 0039 0382 502973-2954; Fax: 0039 0382 502618; E-mail:
58 gr.corazza@smatteo.pv.it
59
60

Abstract

Objectives: There are no data regarding the prevalence of comorbidity (i.e., additional conditions in reference to an index disease) and multimorbidity (i.e., co-occurrence of multiple diseases in which no one holds priority) in patients with liver cirrhosis. We sought to determine the rate and differences between co-multimorbidity depending on the aetiology of cirrhosis. **Design:** This is a sub-analysis of the SMAC study. We have analysed demographic, clinical characteristics, and rate of co-/multimorbidity of patients with liver cirrhosis depending on the aetiology - alcoholic, infectious, and non-alcoholic fatty liver disease (NAFLD). A multivariable analysis for factors associated with multimorbidity was fitted. **Setting:** Single-centre, cross-sectional study conducted in a tertiary referral, academic, internal medicine ward in northern Italy (November 2017-November 2019). **Participants:** Data from 1433 patients previously enrolled in the SMAC study were assessed; only those with liver cirrhosis were eventually included. **Results:** Of the 1433 patients, 172 (median age 79 years, IQR 67-84; 83 females) had liver cirrhosis. Patients with cirrhosis displayed higher median Cumulative Illness Rating Scale (CIRS) comorbidity (4, IQR 3-5; $p=0.01$) and severity (1.85, IQR 1.6-2.0; $p<0.001$) indexes, and lower educational level (103 patients, 59.9%; $p=0.003$). Patients with alcohol cirrhosis were significantly younger (median 65 years, IQR 56-79) than patients with cirrhosis of other aetiologies ($p<0.001$) and more commonly males (25 patients, 75.8%). Comorbidity was more prevalent in patients with alcohol cirrhosis (13 patients, 39.4%) and multimorbidity more prevalent in viral (64 patients, 81.0%) and NAFLD (52 patients, 86.7%) cirrhosis ($p=0.015$). In a multivariable model for factors associated with multimorbidity, a CIRS comorbidity index >3 (OR 2.81, 95% CI 1.14-6.93, $p=0.024$) and admission related to cirrhosis (OR 0.19, 95% CI 0.07-0.54, $p=0.002$) were the only significant associations.

1
2
3 **Conclusions:** Comorbidity is more common in alcohol cirrhosis compared to other
4
5 aetiologies in a hospital, internal medicine setting.
6

7 **Keywords:** ageing; alcohol; chronic liver disease; multimorbidity.
8
9

10 11 12 13 14 15 16 17 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 18
19 • We collected prospective data from patients with liver cirrhosis admitted to an internal
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
• We collected prospective data from patients with liver cirrhosis admitted to an internal medicine ward and we have described for the first time the rates of, and factors associated with, comorbidity and multimorbidity in this population.
- We have also divided patients according to the liver aetiology, finding that those with alcohol cirrhosis were significantly younger than patients with infectious or non-alcoholic liver disease cirrhosis and more commonly males.
- The sample size was rather small, especially for some cirrhosis aetiologies, so we had to exclude some patients from our analysis.
- Generalisability of our results is limited to the internal medicine setting, and cannot be applied to other specialty settings, nor to the primary care.

Introduction

Clinical complexity is one of the most challenging issues of modern medicine, especially in internal medicine, and it originates from the interaction between the patient's own factors and other external, but contextual, factors (1-2). Its fundamental attributes are represented by interconnectedness, non-linearity, context-sensitivity, and unpredictability (3-5). Among the most important determinants of clinical complexity, the association of multiple chronic conditions within the same patient is certainly one of the most relevant, and for some years multiple chronic conditions and clinical complexity have been identified in each other. However, subsequent studies have demonstrated that clinical complexity is something more and different compared to the mere disease associations, and it includes both biological (i.e., ageing, multiple chronic conditions, frailty, mental impairment, malnutrition, dependency) and non-biological (i.e., socioeconomic, cultural, environmental, behavioural) variables (3,6,7). Further, multiple chronic conditions can be split into two important clinical categories, namely comorbidity, which indicates the combined effects of additional conditions in reference to an index disease under study, and multimorbidity, which indicates the mere co-occurrence of multiple diseases within the same individual, in which no single disease holds priority (8,9). The distinction between comorbidity and multimorbidity may translate into substantial differences in the pathways of care.

Among various end-stage organ failure, liver cirrhosis is an example of clinical complexity and of systemic condition (10). To mention a few disease-related manifestations, ascites, hepatic encephalopathy, cell blood count alterations, coagulopathy, and gastrointestinal bleeding, all have a negative impact on both physical and mental functioning (11). Additionally, patients with cirrhosis frequently have multiple chronic conditions (12-14), although their impact on prognosis remains unclear (14), and despite a distinction between comorbidity and multimorbidity has never been assessed. Besides its biological complexity, the impact of socioeconomic factors, i.e., education, marital and employment status,

1
2
3 household income, is an additional detrimental factor the effects of which appear to vary
4 according to disease aetiology (15,16), and to have a relevant impact on survival and overall
5 patients' management (15,17). In particular, different networks and trajectories of disease
6 association might be noticed according to the specific aetiology of cirrhosis, such as chronic
7 viral hepatitis (HBV-, HCV-related), alcoholic liver disease, autoimmune liver disease, and
8 non-alcoholic fatty liver disease (NAFLD) (18).
9

10
11
12 On these bases, we sought to analyse a population of cirrhotic patients admitted to an
13 internal medicine ward, in order to highlight whether any difference exists in the rate of
14 comorbidity, multimorbidity and other determinants of clinical complexity in relation to
15 patients' characteristics and to the specific aetiology of liver cirrhosis.
16
17

18 **Methods**

19 *Study population*

20
21 For the purpose of this paper, data from the San MATteo Complexity (SMAC) study were
22 used. The SMAC study is a large ongoing prospective research project regarding clinical
23 complexity (NCT03439410) conducted at our Institution (IRCCS San Matteo Hospital
24 Foundation, University of Pavia, Pavia, Italy) (19-22). The primary aim of the SMAC study
25 is the validation of a tool for assessing clinical complexity in hospitalized patients. Several
26 sociodemographic and clinical characteristics were collected, including age, sex,
27 socioeconomic status, cause of admission, polypharmacy, and major health outcomes (i.e.,
28 in-hospital death, hospital readmissions, death at follow-up). Specifically, adult patients
29 (age >18 years) admitted to our internal medicine ward, regardless of the cause, were
30 consecutively enrolled from November 2017 to November 2019 by trained physicians and
31 by a research nurse. All patients' data were collected by the trained researchers, so do
32 avoid potential biases. Terminally ill patients with an expected prognosis of less than 48
33 hours and denial of informed consent were the only exclusion criteria. The telephone follow-
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 up, scheduled every 4 months for the first year after discharge, and yearly thereafter for up
4
5 to five years, is still ongoing.
6
7
8
9

10 *Selection of cirrhotic patients*

11
12 In the present study, which is a sub-analysis of the SMAC study, among all enrolled patients
13
14 (n. 1433), we selected those with a clinical diagnosis of liver cirrhosis according to the
15
16 International Classification of Diseases (ICD) 9 codes (i.e., 571, 571.2, 571.5, 571.6, 571.4,
17
18 571.40, 571.41, 571.49, 571.8, 571.9). Hence, this is a cross-sectional study, in which we
19
20 used data in a single timepoint (i.e., the time of discharge of the patient). Also, the discharge
21
22 letter of each cirrhotic patient was reviewed for confirming the aetiology of the disease,
23
24 according to internationally-recognised guidelines and recommendations (23-25). Among
25
26 all causes of cirrhosis, we categorised patients as having alcohol, viral (either by HBV
27
28 and/or HCV infection), or NAFLD cirrhosis. Patients with undetermined causes of cirrhosis
29
30 or with rare causes of cirrhosis (e.g., autoimmune liver disease, sclerosing cholangitis,
31
32 others) were excluded. In case of multiple aetiologies, we selected either the leading or the
33
34 more lasting cause of liver injury. Liver cirrhosis was diagnosed on the basis of clinical
35
36 features, laboratory characteristics, imaging (abdominal ultrasound, liver fibroscan), and
37
38 liver biopsy (when available) (25). Alcohol cirrhosis was diagnosed when a history of
39
40 persistent alcohol consumption/abuse was ascertained, while the diagnosis of viral
41
42 hepatitis relied on serology. NAFLD cirrhosis was diagnosed when all other causes of
43
44 cirrhosis were ruled out, and other clear metabolic alterations were present (i.e.,
45
46 obesity/overweight, dyslipidaemia, oral glucose intolerance or diabetes mellitus type II); in
47
48 some cases, the diagnosis was also confirmed by biopsy.
49
50
51
52
53
54
55
56
57

58 *Definition of comorbidity and multimorbidity*

59
60

1
2
3 Considering its clinical features and the progressive disease course, liver cirrhosis could
4 ideally represent a model of comorbidity or multimorbidity, both encompassing the concept
5 of multiple chronic conditions. In this regard, recently standardised definitions for
6 comorbidity and multimorbidity (8,9) have been introduced to distinguish patients in the
7 context of multiple chronic conditions. As already stated, comorbidity indicates the
8 combined effects of additional conditions in reference to an index disease under study,
9 whereas multimorbidity indicates the mere co-occurrence of multiple diseases within the
10 same individual, in which no single disease holds priority. Accordingly, specific novel
11 medical subject heading (MeSH) definitions have been released for indexing purposes.⁸
12 Following these definitions, all our patients have been categorised as having either
13 comorbidity or multimorbidity by an expert physician who reviewed all patients' discharge
14 letters. For example, patients having only complications of liver cirrhosis (namely cirrhosis
15 decompensation, gastrointestinal bleeding, hepatic encephalopathy, ascites) have been
16 categorised as being comorbid (i.e., all these conditions are dependent on liver cirrhosis,
17 which is therefore the index disease), while patients with association with other clinically
18 relevant conditions (e.g., a patient with liver cirrhosis, ischemic heart disease, diabetes
19 mellitus type II, and chronic kidney failure) have been categorised as having multimorbidity.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 *Aims of the study and variables included*

46 As a primary aim, we looked at the rates of co- or multimorbidity and other possible
47 determinants of clinical complexity in cirrhotic patients, compared to the whole SMAC
48 cohort. As a secondary aim, we compared the rate of comorbidity and multimorbidity
49 according to the aetiology of liver cirrhosis, as well as other potential determinants of
50 clinical complexity, including sex, BMI, schooling (categorised into <8 or ≥8, which is the
51 legal number of compulsory education), income (categorised into <1000€/month or
52 ≥1000€/month), Cumulative Illness Rating Scale (CIRS) comorbidity e severity index,
53
54
55
56
57
58
59
60

1
2
3 Edmonton Frail Scale (a score >5 indicates being frail) (26), Barthel index (a score <60
4 indicates dependency) (27), Short Blessed Test (SBT; a score >9 indicated cognitive
5 impairment) (28), length of stay (LOS). The causes of admission to hospital were
6
7
8 categorised as either related or unrelated to liver cirrhosis and were included in the
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Edmonton Frail Scale (a score >5 indicates being frail) (26), Barthel index (a score <60 indicates dependency) (27), Short Blessed Test (SBT; a score >9 indicated cognitive impairment) (28), length of stay (LOS). The causes of admission to hospital were categorised as either related or unrelated to liver cirrhosis and were included in the multivariable analysis. Finally, we sought to determine the factors affecting the risk of having multimorbidity according to the aetiology.

Statistical analysis and ethics considerations

Continuous data were described with the median and interquartile range (IQR) and compared with the Mann Whitney U test or the Kruskal Wallis test. Categorical data were reported as counts and percent and compared with the Fisher exact test. Based on clinical considerations we chose a priori a series of candidate variables, which were considered the most relevant patient clinical characteristics according to the aetiology of cirrhosis. These were checked for collinearity and were included in a logistic multivariable model. The area under the model ROC curve was computed as a measure of model performance. The model calibration was assessed graphically using the calibration plot and the corresponding statistic test was computed. We did not formally calculate the sample size for this sub-study, as all patients from the SMAC registry were included. However, given the overall sample of 1433 patients and 172 cirrhotic patients, we were able to fit a multivariable model with up to 17 predictors without overfitting. The software Stata 17 (StataCorp, College Station, TX, USA) was used for all computations. The study follows the STROBE recommendations for quality assurance.

All patients provided written informed consent prior to study enrolment and the study protocol was approved by the local Ethics Committee (San Matteo Hospital Foundation; 3 July 2017, Protocol number 2017/0019414). The consent for publication of data was also obtained by all patients. This research was performed in accordance with the Declaration of

1
2
3 Helsinki. The full dataset of the study cannot be shared publicly at this stage since the SMAC
4
5 study is still ongoing. Additional data can be shared upon request to the authors.
6
7
8
9
10

11 Patient and public involvement

12
13
14 None.
15
16
17

18 **Results**

19
20 Table 1 reports the baseline characteristics of the entire cohort of 172 cirrhotic patients
21
22 (median age 79 years, IQR 67-84; 83 females) compared to the other 1261 patients (median
23
24 age 80 years, IQR 70-86; 685 females) included in the SMAC study. Patients with cirrhosis
25
26 displayed higher CIRS comorbidity (4, IQR 3-5, $p=0.01$) and severity (1.85, IQR 1.6-2.0,
27
28 $p<0.001$) indexes, and lower educational level (103 patients, 59.9%, $p=0.002$). No other
29
30 significantly different results were noticed for sex, nutritional status, frailty, dependency,
31
32 cognitive impairment, income, and living alone.
33
34
35

36
37 Table 2 reports the main demographic and clinical characteristics of patients with liver
38
39 cirrhosis according to their aetiologies. Notably, we found that patients with alcohol cirrhosis
40
41 were significantly younger (median age 65 years, IQR 56-79) and more commonly males
42
43 (25 patients, 75.8%) than patients with cirrhosis of other aetiologies ($p<0.001$). Further, BMI
44
45 was significantly higher (27.1, IQR 23.7-31.8) in patients with NAFLD cirrhosis ($p<0.001$).
46
47 No differences among groups were noticed in terms of CIRS comorbidity and severity
48
49 indexes, frailty, dependency, cognitive impairment, living alone, schooling, and length of
50
51 stay. Regarding comorbidity and multimorbidity, we found a significant ($p=0.015$) difference
52
53 in their prevalence among the three liver aetiologies under study ($p=0.015$). Particularly,
54
55 comorbidity was more prevalent in patients with alcohol cirrhosis (13 patients, 39.4%), while
56
57
58
59
60

1
2
3 multimorbidity was more prevalent in viral (64 patients, 81.0%) and NAFLD (52 patients,
4
5 86.7%) cirrhosis.
6

7
8 Finally, in a multivariable model (Table 3) we found that a CIRS comorbidity index >3 (OR
9
10 2.81, 95% CI 1.14-6.93, p=0.024) was significantly correlated with having multimorbidity. On
11
12 the contrary, admission related to cirrhosis (OR 0.19, 95% CI 0.07-0.54, p=0.002) was
13
14 inversely correlated with the presence of multimorbidity.
15
16

17 18 19 **Discussion**

20
21 We herein found some important differences regarding baseline clinical characteristics of
22
23 cirrhotic patients compared to the whole cohort of patients hospitalised in an academic,
24
25 internal medicine ward. In particular, cirrhotic patients had an even greater CIRS indexes
26
27 (comorbidity and severity) and higher rates of co- and multimorbidity, as well as a lower
28
29 educational level, despite being similarly frail and dependent, and had a similarly impaired
30
31 cognitive function. These latter results were not unexpected, considering that our controls
32
33 were similarly old (median age 80 years vs 78) and hospitalised. In a similar large,
34
35 prospective, and multicentric study, although including only patients greater than 65 years
36
37 old, enrolled in internal medicine and geriatric wards, among 6193 patients, liver cirrhosis
38
39 was found in 315 (5%); of these, 43% were multimorbid, 44% had cognitive impairment, and
40
41 51% were disabled (29).
42
43
44
45

46
47 The present study is the first in which a distinction between comorbidity and multimorbidity
48
49 in a population of hospitalised patients with a specific chronic disease was performed.
50
51 Indeed, previous studies have analysed the presence of multiple chronic conditions in
52
53 patients with liver disease (12-14), but the term “comorbidity” has been used with a different
54
55 meaning, outside the current MeSH definition (8). In these studies (12-14), it was evident
56
57 that patients with cirrhosis suffered from many other disorders, but they have not been
58
59
60

1
2
3 identified as either a consequence of cirrhosis itself or its aetiologic factor (i.e.,
4 comorbidities) or as separate entities (i.e., multimorbidity).
5
6

7
8 Regarding differences among cirrhosis aetiologies in our study, we found that viral (median
9 age 81 years, IQR 77-85) and NAFLD (median age 78 years, IQR 65-82) cirrhotic patients
10 were significantly older than alcohol cirrhosis patients (median age 65 years, IQR 56-79),
11 as already demonstrated in other studies which, however, were conducted in completely
12 different settings (e.g., population level or specialistic settings) (12,30,31). This translates
13 into a higher rate of multimorbidity -that we actually found- possibly due to the stochastic
14 accumulation of different disorders with advanced age. Conversely, in patients with alcohol
15 cirrhosis, the higher rate of comorbidity could be interpreted as a direct consequence of
16 alcohol abuse which is a strong and well-known risk factor for multiple organ involvement,
17 often underlying a common psychopathological basis (32). Additionally, in the alcohol
18 cirrhosis group, we found a clear male predominance, while in the other groups there was
19 not a prominent difference with regard to biological sex, and this is consistent with previous
20 reports (31,33). Of note, although a higher prevalence of alcoholic cirrhosis in male patients
21 is expected, the gap in alcohol consumption between men and women has been
22 progressively narrowing over the last years (34).
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 Admission related to cirrhosis was found to be inversely related to the presence of
43 multimorbidity, while CIRS was directly related to multimorbidity. These correlations
44 represent a counterproof of the validity of the classification applied for categorizing patients
45 as having either co- or multimorbidity. for example, a patient with cirrhosis and many other
46 randomly associated multiple chronic conditions (multimorbid) would be more likely to be
47 admitted to hospital due to one of these many multiple chronic conditions compared to a
48 patient with cirrhosis and its classical comorbidities, such as ascites, gastrointestinal
49 bleeding, or encephalopathy (comorbid). It is not surprising that, according to a recent expert
50 consensus, the evaluation of socioeconomic factors, educational status, and comorbid
51
52
53
54
55
56
57
58
59
60

1
2
3 psychiatric illness should all be taken into account by a multidisciplinary team in alcohol
4
5 cirrhosis patients (32). In fact, a low educational level was found to be common in our alcohol
6
7 cirrhosis patients, and interventions aimed at improving one's knowledge of the disease may
8
9 translate into a therapeutic advantage.
10
11
12
13

14 **Limitations**

15
16 We are aware that our study has some limitations that should be mentioned. The sample
17
18 size was rather small, especially for some cirrhosis aetiologies (e.g., autoimmune liver
19
20 disease), so we had to exclude these patients from our analysis. Hence, a wider
21
22 multivariable analysis could not be made. Even if our data should be considered as
23
24 preliminary in this field, a distinction between co- and multimorbidity could potentially aid
25
26 decision-making in cirrhotic patients, in whom a prioritisation of the clinical problems to be
27
28 solved is mandatory. Also, our data should be interpreted in the light of the specific setting
29
30 of enrolment, in which patients admitted are usually older than in others. Hence, our data
31
32 cannot be generalised to other settings, like that of the population level or the primary care.
33
34 Nevertheless, this study had some strengths, including a prospective collection of data, not
35
36 administrative based, but collected during the hospitalisation by a dedicated and qualified
37
38 staff of healthcare professionals who had been instructed before study commencement (20).
39
40
41
42
43
44
45
46

47 **Conclusion**

48
49 To conclude, we have performed the first study focusing on the distinction of comorbidity
50
51 and multimorbidity in a cohort of patients with a specific chronic condition. We found that
52
53 patients with alcoholic cirrhosis had a high comorbidity rate, while the other aetiologies -viral
54
55 and NAFLD- were mostly multimorbid due to ageing. How these characteristics may
56
57 translate into distinct and personalised clinical management should be further investigated.
58
59
60

Data availability statement

The full dataset of the study cannot be shared publicly at this stage, since the SMAC study is still ongoing. Additional data can be shared upon request to the authors (please contact Prof. Gino Roberto Corazza at the email address provided).

Ethics statements

Patient consent for publication

Acquired by all patients before enrolment.

Ethics approval

The study protocol was approved by the local Ethics Committee (San Matteo Hospital Foundation; 3 July 2017, Protocol number 2017/0019414). This research was performed in accordance with the Declaration of Helsinki. There were no uneducated participants in this study.

Competing interests

The authors report no conflict of interest.

Funding

This research is part of a project for the study of clinical complexity (SMAC study) funded by San Matteo Hospital Foundation - Italian Ministry of Health (Progetto di Ricerca Corrente 2017; award number not applicable). The funding source had no role in the design, execution, analyses, and interpretation of the data.

Authors contributions

1
2
3 All authors participated in the drafting of the manuscript or critical revision of the manuscript
4 for important intellectual content and provided approval of the final submitted version.
5
6 Individual contributions are as follow: GRC designed and coordinated the study; MVL and
7
8 AB drafted the manuscript; MVL, AB, GC, ASB, LP, GB, and ADS organised data collection
9
10 conducted the study and/or enrolled patients; CK designed and performed statistical
11
12 analysis, interpreted data, and revised the manuscript; GRC made the final critical revision
13
14 for important intellectual content. All authors approved the final version of the paper.
15
16
17
18
19
20

21 **Acknowledgements**

22
23 None.
24
25
26
27

28 **Abbreviations:** CIRS, Cumulative Illness Rating Scale; IQR, interquartile range; LOS,
29 length of stay; MeSH, medical subject heading; NAFLD, non-alcoholic fatty liver disease;
30
31 SBT, Short Blessed Test; SMAC, San MAteo Complexity.
32
33
34
35
36

37 **References**

- 38
39
40
41
42 1. Safford MM, Allison JJ, Kiefe CI. Patient complexity: more than comorbidity. the
43 vector model of complexity. *J Gen Intern Med.* 2007;3:382-390.
44
45
46 2. Turner BJ, Cuttler L. The complexity of measuring clinical complexity. *Ann Intern*
47 *Med.* 2011;155:851-852.
48
49
50 3. Corazza GR, Formagnana P, Lenti MV. Bringing complexity into clinical practice: An
51 internistic approach. *Eur J Intern Med.* 2019;61:9-14.
52
53
54 4. Goldenfeld N, Kadanoff LP. Simple lessons from complexity. *Science.* 1999;284:87-
55
56
57
58 89.
59
60

- 1
2
3 5. Plsek PE, Greenhalgh T. Complexity science: The challenge of complexity in health
4 care. *BMJ*. 2001;323:625-628.
5
6
- 7 6. Grant RW, Ashburner JM, Hong CS, Chang Y, Barry MJ, Atlas SJ. Defining patient
8 complexity from the primary care physician's perspective: a cohort study. *Ann Intern*
9 *Med*. 2011;155:797-804.
10
11
- 12 7. Hong CS, Atlas SJ, Ashburner JM, et al. Evaluating a model to predict primary care
13 physician-defined complexity in a large academic primary care practice-based
14 research network. *J Gen Intern Med*. 2015;30:1741-1747.
15
16
- 17 8. Tugwell P, Knottnerus JA. Multimorbidity and comorbidity are now separate MESH
18 headings. *J Clin Epidemiol*. 2019 [Epub ahead of print]
19
20
- 21 9. Nicholson K, Makovski TT, Griffith LE, Raina P, Stranges S, van den Akker M.
22 Multimorbidity and comorbidity revisited: refining the concepts for international health
23 research. *J Clin Epidemiol*. 2019;105:142-146.
24
25
- 26 10. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. *Lancet*. 2014;383:1749-1761.
27
28
- 29 11. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of
30 survival in cirrhosis: a systematic review of 118 studies. *J Hepatol*. 2006;44:217-231.
31
32
- 33 12. Yang TW, Wang CC, Tsai MC, Wang YT, Tseng MH, Lin CC. Comorbidities and
34 outcome of alcoholic and non-alcoholic liver cirrhosis in Taiwan: a population-based
35 study. *Int J Environ Res Public Health*. 2020;17:2825.
36
37
- 38 13. Vaz J, Eriksson B, Strömberg U, Buchebner D, Midlöv P. Incidence, aetiology and
39 related comorbidities of cirrhosis: a Swedish population-based cohort study. *BMC*
40 *Gastroenterol*. 2020;20:84.
41
42
- 43 14. Jepsen P. Comorbidity in cirrhosis. *World J Gastroenterol*. 2014;20:7223-7230.
44
45
- 46 15. Jepsen P, Vilstrup H, Andersen PK, Sørensen HT. Socioeconomic status and survival
47 of cirrhosis patients: a Danish nationwide cohort study. *BMC Gastroenterol*.
48 2009;9:35.
49
50
51
52
53
54
55
56
57
58
59
60

16. Roesch-Dietlen F, González-Santes M, Sánchez-Maza YJ, ET AL. Influence of socioeconomic and cultural factors in the aetiology of cirrhosis of the liver. *Rev Gastroenterol Mex.* 2021;86:28-35.
17. Vaz J, Strömberg U, Eriksson B, et al. Socioeconomic and marital status among liver cirrhosis patients and associations with mortality: a population-based cohort study in Sweden. *BMC Public Health* 2020. [Epub ahead of print]
18. Menche J, Sharma A, Kitsak M, et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. *Science* 2015;347:1257601.
19. Corazza GR, Klersy C, Formagnana P, Lenti MV, Padula D; Consensus Panel. A consensus for the development of a vector model to assess clinical complexity. *Intern Emerg Med.* 2017;12:1313-1318.
20. Lenti MV, Klersy C, Brera AS, et al. Reproducibility in the assessment of the components of a clinical complexity index. *J Gen Intern Med.* 2019;34:2316-2318.
21. Lenti MV, Klersy C, Brera AS, et al. Clinical complexity and hospital admissions in the December holiday period. *PLoS One.* 2020;15:e0234112.
22. Lenti MV, Klersy C, Brera AS, et al. Aging underlies heterogeneity between comorbidity and multimorbidity frameworks. *Intern Emerg Med.* 2022 [Epub ahead of print]
23. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol.* 2016;64:1388-402.
24. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. *J Hepatol.* 2018;69:154-181.
25. Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. *Lancet.* 2021 Oct 9;398:1359-1376.

- 1
2
3 26. Rolfson DB, Majumdar SR, Tsuyuki RT, Tahir A, Rockwood K. Validity and reliability
4 of the Edmonton Frail Scale. *Age Ageing*. 2006;35:526-9.
5
6
7 27. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. *Md State Med J*.
8 1965;14:61-5.
9
10
11 28. Ball LJ, Bisher GB, Birge SJ. A simple test of central processing speed: an extension
12 of the Short Blessed Test. *J Am Geriatr Soc*. 1999;47:1359-63.
13
14
15 29. De Vincentis A, Vespasiani-Gentilucci U, Costanzo L, et al; REPOSI Investigators.
16 The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of
17 the REPOSI registry. *Age Ageing*. 2021;50:498-504.
18
19
20
21 30. Dam Fialla A, Schaffalitzky de Muckadell OB, Touborg Lassen A. Incidence, aetiology
22 and mortality of cirrhosis: a population-based cohort study. *Scand J Gastroenterol*.
23 2012;47:702-709.
24
25
26 31. Sajja KC, Mohan DP, Rockey DC. Age and ethnicity in cirrhosis. *J Investig Med*.
27 2014;62:920-926.
28
29
30
31 32. Singal AK, Kwo P, Kwong A, et al. Research methodologies to address clinical unmet
32 needs and challenges in alcohol-associated liver disease. *Hepatology*. 2021 [Epub
33 ahead of print]
34
35
36 33. Wilsnack RW, Wilsnack SC, Kristjanson AF, Vogeltanz-Holm ND, Gmel G. Gender
37 and alcohol consumption: patterns from the multinational GENACIS project.
38
39
40
41
42
43
44
45
46
47
48
49 34. Kezer CA, Simonetto DA, Shah VH. Sex differences in alcohol consumption and alcohol-
50 associated liver disease. *Mayo Clin Proc*. 2021;96:1006-1016.
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1. Baseline characteristics of the entire cohort of patients.

	Cirrhotic patients	*Other patients	p value
Total number of patients, n (%)	172 (12.0)	1261 (88.0)	
Age, median (IQR)	79.0 (67.0-84.0)	80.0 (70.0-86.0)	0.275
Sex, n (%)			0.079
M	89 (51.7)	576 (45.7)	
F	83 (48.3)	685 (54.3)	
CIRS comorbidity index, median (IQR)	4.0 (3.0-5.0)	4.0 (2.0-5.0)	0.01
CIRS severity index, median (IQR)	1.85 (1.6-2.0)	1.77 (1.5-1.9)	<0.001
Co- multimorbidity, n (%)			0.003
None	0 (0)	57 (4.6)	
Comorbidity	35 (20.5)	251 (20.4)	
Multimorbidity	136 (79.5)	923 (75.0)	
BMI, median (IQR)	25.1 (21.5-29.2)	24.2 (21.3-27.7)	0.057
Edmonton >5, n (%)			0.724
No	50 (29.1)	377 (30.6)	
Yes	122 (70.9)	854 (69.4)	
Barthel <60, n (%)			0.508
No	134 (77.9)	956 (77.6)	
Yes	38 (22.1)	276 (22.4)	
SBT >9, n (%)			0.870
No	82 (47.9)	578 (47.1)	
Yes	89 (52.1)	649 (52.9)	
Income <1000 €/mon, n (%)			0.935
No	89 (51.7)	641 (52.2)	
Yes	83 (48.3)	587 (47.8)	
Living alone, n (%)			0.439
No	137 (79.6)	944 (76.6)	
Yes	35 (20.4)	288 (23.4)	
Schooling <8, n (%)			0.032
No	69 (40.1)	590 (47.8)	
Yes	103 (59.9)	640 (52.0)	
LOS median (IQR)	14.0 (9.0-20.0)	14.0 (10.0-23.0)	0.018

*This includes all the other patients enrolled in the SMAC study, with the exception of cirrhotic patients, as explained in the text. Abbreviations: BMI, Body Mass Index; CIRS, Cumulative Illness Rating Scale; SBT, Short Blessed Test; LOS, length of stay.

7 **Table 2.** Baseline characteristics of patients with cirrhosis according to the aetiology.

	Alcohol (I)	Viral (II)	NAFLD (III)	p-value
Total number of patients, n (%)	33 (19.2)	79 (45.9)	60 (34.9)	/
Age, median (IQR)	65 (56-79)	81 (77-85)	78 (65-82)	< 0.001 0.007 (II vs III) < 0.001 (II vs I) 0.005 (III vs I)
Sex, n (%)				0.008
Male	25 (75.8)	37 (46.8)	27 (45.0)	
Female	8 (24.2)	42 (53.2)	33 (55.0)	
CIRS comorbidity index, median (IQR)	4.0 (3.0-5.0)	4.0 (3.0- 5.0)	4.0 (3.0- 6.0)	0.314
CIRS severity index, median (IQR)	1.85 (1.62- 1.92)	1.85 (1.62- 2.0)	1.85 (1.69- 2.15)	0.423
Co-multimorbidity, n (%)				0.015
Comorbidity	13 (39.4)	15 (19.0)	8 (13.3)	
Multimorbidity	20 (60.6)	64 (81.0)	52 (86.7)	
BMI, median (IQR)	23.4 (21.5- 29.4)	23.5 (20.5- 26.6)	27.1 (23.7- 31.8)	<0.001 <0.001 (II vs III) 0.11 (II vs I) 0.02 (III vs I)
Edmonton >5, n (%)				0.604
No	11 (33.3)	20 (25.3)	19 (31.7)	
Yes	22 (66.7)	59 (74.7)	41 (68.3)	
Barthel <60				0.164
No	29 (87.9)	57 (72.1)	48 (80)	
Yes	4 (12.1)	22 (27.9)	12 (20)	
Income <1000 €/mon, n (%)				0.523
No	14 (42.4)	43 (54.4)	32 (53.3)	
Yes	19 (57.6)	36 (45.6)	28 (46.7)	
Living alone, n (%)				0.219
No	26 (78.8)	59 (74.7)	52 (86.7)	
Yes	7 (21.2)	20 (25.3)	8 (13.3)	
Schooling <8, n (%)				0.282
No	12 (36.4)	28 (35.4)	29 (48.3)	
Yes	21 (63.6)	51 (64.6)	31 (51.7)	
SBT >9, n (%)				0.102
No	20 (60.6)	31 (39.7)	31 (51.7)	
Yes	13 (39.4)	47 (60.3)	29 (48.3)	
LOS median (IQR)	12.0 (8.0-19.0)	14.0 (9.0- 19.0)	14.0 (10.0-21.5)	0.423

8 Abbreviations: BMI, Body Mass Index; CIRS, Cumulative Illness Rating Scale; SBT, Short Blessed Test; LOS, length of stay.

9

10 **Table 3.** Multivariable analysis for factors associated with multimorbidity.

	Odds ratio	95% CI	p-value
Sex			
Male	1.0 (reference)		
Female	1.63	0.64-4.14	0.308
Aetiology of cirrhosis			
0.148			
Viral	1.0 (reference)		
NAFLD	0.81	0.27-2.40	0.698
Alcohol	0.35	0.12-1.02	0.055
CIRS comorbidity index >3			
No	1.0 (reference)		
Yes	2.81	1.14-6.93	0.024
Barthel <60			
No	1.0 (reference)		
Yes	2.84	0.61- 13.29	0.186
Admission related to cirrhosis			
No	1.0 (reference)		
Yes	0.19	0.07-0.54	0.002

12 Model Chi² 36.77, p-value<0.001; area under the ROC curve=0.81; calibration belt p=0.615, plot within 95%
 13 CI. Abbreviations: Cumulative Illness Rating Scale, CIRS; NAFLD, non-alcoholic fatty liver disease.

STROBE Statement—checklist of items that should be included in reports of observational studies
 Paper: Determinants of clinical complexity in hospitalized cirrhotic patients by Lenti MV et al.

	Item No.	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4-5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	4-6
Study size	10	Explain how the study size was arrived at	6

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Continued on next page

For peer review only

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	NA
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6-8
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6-8
		(b) Indicate number of participants with missing data for each variable of interest	6-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	6-8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	6-8
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6-8
		(b) Report category boundaries when continuous variables were categorized	6-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	8-10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	8-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	8-10
Generalisability	21	Discuss the generalisability (external validity) of the study results	8-10
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Comorbidity and multimorbidity in cirrhotic patients hospitalised in an internal medicine ward: a monocentric, cross-sectional study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-077576.R2
Article Type:	Original research
Date Submitted by the Author:	21-Mar-2024
Complete List of Authors:	Lenti, Marco; Università degli Studi di Pavia, First Department of Internal Medicine Ballesio, Alessia; University of Pavia, Department of Internal Medicine and Medical Therapeutics; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Croce, Gabriele; University of Pavia, Department of Internal Medicine and Medical Therapeutics; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Brera, Alice Silvia; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Padovini, Lucia; University of Pavia, Department of Internal Medicine and Medical Therapeutics; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Bertolino, Giampiera; Fondazione IRCCS Policlinico San Matteo, First Department of Internal Medicine Di Sabatino, Antonio; Università degli Studi di Pavia, First Department of Medicine Klersy, Catherine; Fondazione IRCCS Policlinico San Matteo, Service of Clinical Epidemiology & Biometry, Research Department Corazza, Gino Roberto; Fondazione IRCCS Policlinico San Matteo, Department of Internal Medicine
Primary Subject Heading:	Gastroenterology and hepatology
Secondary Subject Heading:	General practice / Family practice
Keywords:	Aging, Adult gastroenterology < GASTROENTEROLOGY, Hepatobiliary disease < GASTROENTEROLOGY

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Comorbidity and multimorbidity in cirrhotic patients hospitalised in an internal medicine ward: a monocentric, cross-sectional study

Marco Vincenzo Lenti,^{1,2} MD, Alessia Ballesio,^{1,2} MD, Gabriele Croce,^{1,2} MD, Alice Silvia Brera,² BSc, Lucia Padovini,^{1,2} MD, Giampiera Bertolino,² MD, Antonio Di Sabatino,^{1,2} MD, Catherine Klersy,³ MD, Gino Roberto Corazza,^{1,2} MD

¹Department of Internal Medicine and Medical Therapeutics, University of Pavia, Pavia, Italy;

²First Department of Internal Medicine, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; ³Clinical Epidemiology & Biometry, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

Correspondence to: Prof. Gino Roberto Corazza, Emeritus Professor of Internal Medicine, Clinica Medica I, Fondazione IRCCS Policlinico San Matteo, Viale Golgi 19, 27100 Pavia, Italy

E-mail: gr.corazza@smatteo.pv.it

Abstract

Objectives: There are no data regarding the prevalence of comorbidity (i.e., additional conditions in reference to an index disease) and multimorbidity (i.e., co-occurrence of multiple diseases in which no one holds priority) in patients with liver cirrhosis. We sought to determine the rate and differences between co-multimorbidity depending on the aetiology of cirrhosis.

Design: This is a sub-analysis of the SMAC study. We have analysed demographic, clinical characteristics, and rate of co-/multimorbidity of patients with liver cirrhosis depending on the aetiology - alcoholic, infectious, and non-alcoholic fatty liver disease (NAFLD). A multivariable analysis for factors associated with multimorbidity was fitted.

1
2
3 **Setting:** Single-centre, cross-sectional study conducted in a tertiary referral, academic,
4
5 internal medicine ward in northern Italy (Novembre 2017-November 2019).
6

7 **Participants:** Data from 1433 patients previously enrolled in the SMAC study were
8
9 assessed; only those with liver cirrhosis were eventually included.
10

11 **Results:** Of the 1433 patients, 172 (median age 79 years, IQR 67-84; 83 females) had liver
12
13 cirrhosis. Patients with cirrhosis displayed higher median Cumulative Illness Rating Scale
14
15 (CIRS) comorbidity (4, IQR 3-5; $p=0.01$) and severity (1.85, IQR 1.6-2.0; $p<0.001$) indexes,
16
17 and lower educational level (103, 59.9%; $p=0.003$). Patients with alcohol cirrhosis were
18
19 significantly younger (median 65 years, IQR 56-79) than patients with cirrhosis of other
20
21 aetiologies ($p<0.001$) and more commonly males (25, 75.8%). Comorbidity was more
22
23 prevalent in patients with alcohol cirrhosis (13, 39.4%) and multimorbidity more prevalent in
24
25 viral (64, 81.0%) and NAFLD (52, 86.7%) cirrhosis ($p=0.015$). In a multivariable model for
26
27 factors associated with multimorbidity, a CIRS comorbidity index >3 (OR 2.81, 95% CI 1.14-
28
29 6.93, $p=0.024$) and admission related to cirrhosis (OR 0.19, 95% CI 0.07-0.54, $p=0.002$)
30
31 were the only significant associations.
32
33
34
35
36

37 **Conclusions:** Comorbidity is more common in alcohol cirrhosis compared to other
38
39 aetiologies in a hospital, internal medicine setting.
40
41
42
43

44 **Keywords:** ageing; alcohol; chronic liver disease; multimorbidity.
45
46
47
48

49 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 51 • We collected prospective data from patients with liver cirrhosis admitted to an internal
52
53 medicine ward and we have described the rates of, and factors associated with,
54
55 comorbidity and multimorbidity in this population.
56
57
58
59
60

- We have also divided patients according to the liver aetiology, finding that those with alcohol cirrhosis were significantly younger than patients with infectious or non-alcoholic liver disease cirrhosis and more commonly males.
- The sample size was rather small, especially for some cirrhosis aetiologies, so we had to exclude some patients from our analysis.
- Generalisability of our results is limited to the internal medicine setting, and cannot be applied to other specialty settings, nor to primary care.

INTRODUCTION

Clinical complexity is one of the most challenging issues of modern medicine, especially in internal medicine, and it originates from the interaction between the patient's own factors and other external, but contextual, factors (1-2). Its fundamental attributes are represented by interconnectedness, non-linearity, context-sensitivity, and unpredictability (3-5). Among the most important determinants of clinical complexity, the association of multiple chronic conditions within the same patient is certainly one of the most relevant, and for some years multiple chronic conditions and clinical complexity have been identified in each other. However, subsequent studies have demonstrated that clinical complexity is something more and different compared to the mere disease associations, and it includes both biological (i.e., ageing, multiple chronic conditions, frailty, mental impairment, malnutrition, dependency) and non-biological (i.e., socioeconomic, cultural, environmental, behavioural) variables (3,6,7). Further, multiple chronic conditions can be split into two important clinical categories, namely comorbidity, which indicates the combined effects of additional conditions in reference to an index disease under study, and multimorbidity, which indicates the mere co-occurrence of multiple diseases within the same individual, in which no single

1
2
3 disease holds priority (8,9). The distinction between comorbidity and multimorbidity may
4
5 translate into substantial differences in the pathways of care.
6

7
8 Among various end-stage organ failure, liver cirrhosis is an example of clinical complexity
9
10 and of systemic condition (10). To mention a few disease-related manifestations, ascites,
11
12 hepatic encephalopathy, cell blood count alterations, coagulopathy, and gastrointestinal
13
14 bleeding, all have a negative impact on both physical and mental functioning (11).
15
16 Additionally, patients with cirrhosis frequently have multiple chronic conditions (12-14),
17
18 although their impact on prognosis remains unclear (14), and despite a distinction between
19
20 comorbidity and multimorbidity has never been assessed. Besides its biological complexity,
21
22 the impact of socioeconomic factors, i.e., education, marital and employment status,
23
24 household income, is an additional detrimental factor the effects of which appear to vary
25
26 according to disease aetiology (15,16), and to have a relevant impact on survival and overall
27
28 patients' management (15,17). In particular, different networks and trajectories of disease
29
30 association might be noticed according to the specific aetiology of cirrhosis, such as chronic
31
32 viral hepatitis (HBV-, HCV-related), alcoholic liver disease, autoimmune liver disease, and
33
34 non-alcoholic fatty liver disease (NAFLD) (18).
35
36
37
38

39
40 On these bases, we sought to analyse a population of cirrhotic patients admitted to an
41
42 internal medicine ward, in order to highlight whether any difference exists in the rate of
43
44 comorbidity, multimorbidity and other determinants of clinical complexity in relation to
45
46 patients' characteristics and to the specific aetiology of liver cirrhosis.
47
48
49

50 51 **METHODS**

52 53 *Study population*

54
55 For the purpose of this paper, data from the San MAteeo Complexity (SMAC) study were
56
57 used. The SMAC study is a large ongoing prospective research project regarding clinical
58
59 complexity (NCT03439410) conducted at our Institution (IRCCS San Matteo Hospital
60

1
2
3 Foundation, University of Pavia, Pavia, Italy) (19-22). The primary aim of the SMAC study
4 is the validation of a tool for assessing clinical complexity in hospitalized patients. Several
5 sociodemographic and clinical characteristics were collected, including age, sex,
6 socioeconomic status, cause of admission, polypharmacy, and major health outcomes (i.e.,
7 in-hospital death, hospital readmissions, death at follow-up). Specifically, adult patients
8 (age >18 years) admitted to our internal medicine ward, regardless of the cause, were
9 consecutively enrolled from November 2017 to November 2019 by trained physicians and
10 by a research nurse. All patients' data were collected by the trained researchers, so do
11 avoid potential biases. Terminally ill patients with an expected prognosis of less than 48
12 hours and denial of informed consent were the only exclusion criteria. The telephone follow-
13 up, scheduled every 4 months for the first year after discharge, and yearly thereafter for up
14 to five years, is still ongoing.

32 33 *Selection of cirrhotic patients*

34
35 In the present study, which is a sub-analysis of the SMAC study, among all enrolled patients
36 (n. 1433), we selected those with a clinical diagnosis of liver cirrhosis according to the
37 International Classification of Diseases (ICD) 9 codes (i.e., 571, 571.2, 571.5, 571.6, 571.4,
38 571.40, 571.41, 571.49, 571.8, 571.9). Hence, this is a cross-sectional study, in which we
39 used data in a single timepoint (i.e., the time of discharge of the patient). Also, the discharge
40 letter of each cirrhotic patient was reviewed for confirming the aetiology of the disease,
41 according to internationally-recognised guidelines and recommendations (23-25). Among
42 all causes of cirrhosis, we categorised patients as having alcohol, viral (either by HBV
43 and/or HCV infection), or NAFLD cirrhosis. Patients with undetermined causes of cirrhosis
44 or with rare causes of cirrhosis (e.g., autoimmune liver disease, sclerosing cholangitis,
45 others) were excluded. In case of multiple aetiologies, we selected either the leading or the
46 more lasting cause of liver injury. Liver cirrhosis was diagnosed on the basis of clinical
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 features, laboratory characteristics, imaging (abdominal ultrasound, liver fibroscan), and
4
5 liver biopsy (when available) (25). Alcohol cirrhosis was diagnosed when a history of
6
7 persistent alcohol consumption/abuse was ascertained, while the diagnosis of viral
8
9 hepatitis relied on serology. NAFLD cirrhosis was diagnosed when all other causes of
10
11 cirrhosis were ruled out, and other clear metabolic alterations were present (i.e.,
12
13 obesity/overweight, dyslipidaemia, oral glucose intolerance or diabetes mellitus type II); in
14
15 some cases, the diagnosis was also confirmed by biopsy.
16
17
18
19
20

21 *Definition of comorbidity and multimorbidity*

22
23 Considering its clinical features and the progressive disease course, liver cirrhosis could
24
25 ideally represent a model of comorbidity or multimorbidity, both encompassing the concept
26
27 of multiple chronic conditions. In this regard, recently standardised definitions for
28
29 comorbidity and multimorbidity (8,9) have been introduced to distinguish patients in the
30
31 context of multiple chronic conditions. As already stated, comorbidity indicates the
32
33 combined effects of additional conditions in reference to an index disease under study,
34
35 whereas multimorbidity indicates the mere co-occurrence of multiple diseases within the
36
37 same individual, in which no single disease holds priority. Accordingly, specific novel
38
39 medical subject heading (MeSH) definitions have been released for indexing purposes.⁸
40
41 Following these definitions, all our patients have been categorised as having either
42
43 comorbidity or multimorbidity by an expert physician who reviewed all patients' discharge
44
45 letters. For example, patients having only complications of liver cirrhosis (namely cirrhosis
46
47 decompensation, gastrointestinal bleeding, hepatic encephalopathy, ascites) have been
48
49 categorised as being comorbid (i.e., all these conditions are dependent on liver cirrhosis,
50
51 which is therefore the index disease), while patients with association with other clinically
52
53 relevant conditions (e.g., a patient with liver cirrhosis, ischemic heart disease, diabetes
54
55 mellitus type II, and chronic kidney failure) have been categorised as having multimorbidity.
56
57
58
59
60

Outcomes and variables

As a primary aim, we looked at the rates of co- or multimorbidity and other possible determinants of clinical complexity in cirrhotic patients, compared to the whole SMAC cohort. As a secondary aim, we compared the rate of comorbidity and multimorbidity according to the aetiology of liver cirrhosis, as well as other potential determinants of clinical complexity, including sex, BMI, schooling (categorised into <8 or ≥ 8 , which is the legal number of compulsory education), income (categorised into $<1000\text{€}/\text{month}$ or $\geq 1000\text{€}/\text{month}$), Cumulative Illness Rating Scale (CIRS) comorbidity e severity index, Edmonton Frail Scale (a score >5 indicates being frail) (26), Barthel index (a score <60 indicates dependency) (27), Short Blessed Test (SBT; a score >9 indicated cognitive impairment) (28), length of stay (LOS). The causes of admission to hospital were categorised as either related or unrelated to liver cirrhosis and were included in the multivariable analysis. Finally, we sought to determine the factors affecting the risk of having multimorbidity according to the aetiology.

Statistical analysis

Continuous data were described with the median and interquartile range (IQR) and compared with the Mann Whitney U test or the Kruskal Wallis test. Categorical data were reported as counts and percent and compared with the Fisher exact test. Based on clinical considerations we chose *a priori* a series of candidate variables, which were considered the most relevant patient clinical characteristics according to the aetiology of cirrhosis. These were checked for collinearity and were included in a logistic multivariable model. For descriptive purposes, the univariable analysis of the candidate variables was also performed. The area under the model ROC curve was computed as a measure of model performance. The model calibration was assessed graphically using the calibration plot

1
2
3 and the corresponding statistic test was computed. We did not formally calculate the
4
5 sample size for this sub-study, as all patients from the SMAC registry were included.
6
7 However, given the overall sample of 172 cirrhotic patients with 36 patients with
8
9 comorbidity, we would be able to fit a multivariable model with up to about four predictors
10
11 without overfitting, according to the 1:10 predictors to event rule. *A posteriori* the good
12
13 calibration of our model with six degrees of freedom was assessed, as described above.
14
15 The software Stata 17 (StataCorp, College Station, TX, USA) was used for all
16
17 computations. The study follows the STROBE recommendations for reporting.
18
19
20
21
22

23 *Ethical considerations*

24 All patients provided written informed consent prior to study enrolment and the study
25
26 protocol was approved by the local Ethics Committee (San Matteo Hospital Foundation; 3
27
28 July 2017, protocol number 2017/0019414). Consent for publication of data was obtained
29
30 from all patients. This research was performed in accordance with the Declaration of
31
32 Helsinki.
33
34
35
36
37
38
39

40 *Patient and public involvement*

41 None.
42
43
44
45

46 **RESULTS**

47
48 Table 1 reports the baseline characteristics of the entire cohort of 172 cirrhotic patients
49
50 (median age 79 years, IQR 67-84; 83 females) compared to the other 1261 patients (median
51
52 age 80 years, IQR 70-86; 685 females) included in the SMAC study. Patients with cirrhosis
53
54 displayed higher CIRS comorbidity (4, IQR 3-5, $p=0.01$) and severity (1.85, IQR 1.6-2.0,
55
56 $p<0.001$) indexes, and lower educational level (103, 59.9%, $p=0.002$). No other significantly
57
58
59
60

1
2
3 different results were noticed for sex, nutritional status, frailty, dependency, cognitive
4
5 impairment, income, and living alone.
6

7
8 Table 2 reports the main demographic and clinical characteristics of patients with liver
9
10 cirrhosis according to their aetiologies. Notably, we found that patients with alcohol cirrhosis
11
12 were significantly younger (median age 65 years, IQR 56-79) and more commonly males
13
14 (25, 75.8%) than patients with cirrhosis of other aetiologies ($p<0.001$). Further, BMI was
15
16 significantly higher (27.1, IQR 23.7-31.8) in patients with NAFLD cirrhosis ($p<0.001$). No
17
18 differences among groups were noticed in terms of CIRS comorbidity and severity indexes,
19
20 frailty, dependency, cognitive impairment, living alone, schooling, and length of stay.
21
22 Regarding comorbidity and multimorbidity, we found a significant ($p=0.015$) difference in
23
24 their prevalence among the three liver aetiologies under study ($p=0.015$). Particularly,
25
26 comorbidity was more prevalent in patients with alcohol cirrhosis (13, 39.4%), while
27
28 multimorbidity was more prevalent in viral (64, 81.0%) and NAFLD (52, 86.7%) cirrhosis.
29
30 Finally, in a multivariable model (Table 3) we found that a CIRS comorbidity index >3 (OR
31
32 2.81, 95% CI 1.14-6.93, $p=0.024$) was significantly correlated with having multimorbidity. On
33
34 the contrary, admission related to cirrhosis (OR 0.19, 95% CI 0.07-0.54, $p=0.002$) was
35
36 inversely correlated with the presence of multimorbidity. Supplementary Figure 1 shows the
37
38 good calibration of the model, while Supplementary Table 1 shows the univariable analysis
39
40 of the candidate variables.
41
42
43
44
45
46
47
48

49 **DISCUSSION**

50
51 We herein found some important differences regarding baseline clinical characteristics of
52
53 cirrhotic patients compared to the whole cohort of patients hospitalised in an academic,
54
55 internal medicine ward. In particular, cirrhotic patients had an even greater CIRS indexes
56
57 (comorbidity and severity) and higher rates of co- and multimorbidity, as well as a lower
58
59 educational level, despite being similarly frail and dependent, and had a similarly impaired
60

1
2
3 cognitive function. These latter results were not unexpected, considering that our controls
4 were similarly old (median age 80 years vs 78) and hospitalised. In a similar large,
5
6 prospective, and multicentre study, although including only patients greater than 65 years
7
8 old, enrolled in internal medicine and geriatric wards, among 6193 patients, liver cirrhosis
9
10 was found in 315 (5%); of these, 43% were multimorbid, 44% had cognitive impairment, and
11
12 51% were disabled (29).
13
14
15

16
17 The present study is the first in which a distinction between comorbidity and multimorbidity
18
19 in a population of hospitalised patients with a specific chronic disease was performed.
20
21 Indeed, previous studies have analysed the presence of multiple chronic conditions in
22
23 patients with liver disease (12-14), but the term “comorbidity” has been used with a different
24
25 meaning, outside the current MeSH definition (8). In these studies (12-14), it was evident
26
27 that patients with cirrhosis suffered from many other disorders, but they have not been
28
29 identified as either a consequence of cirrhosis itself or its aetiologic factor (i.e.,
30
31 comorbidities) or as separate entities (i.e., multimorbidity).
32
33
34

35
36 Regarding differences among cirrhosis aetiologies in our study, we found that viral (median
37
38 age 81 years, IQR 77-85) and NAFLD (median age 78 years, IQR 65-82) cirrhotic patients
39
40 were significantly older than alcohol cirrhosis patients (median age 65 years, IQR 56-79),
41
42 as already demonstrated in other studies which, however, were conducted in completely
43
44 different settings (e.g., population level or speciality settings) (12,30,31). This translates into
45
46 a higher rate of multimorbidity -that we actually found- possibly due to the stochastic
47
48 accumulation of different disorders with advanced age. Conversely, in patients with alcohol
49
50 cirrhosis, the higher rate of comorbidity could be interpreted as a direct consequence of
51
52 alcohol abuse which is a strong and well-known risk factor for multiple organ involvement,
53
54 often underlying a common psychopathological basis (32). Additionally, in the alcohol
55
56 cirrhosis group, we found a clear male predominance, while in the other groups there was
57
58 not a prominent difference with regard to biological sex, and this is consistent with previous
59
60

1
2
3 reports (31,33). Of note, although a higher prevalence of alcoholic cirrhosis in male patients
4
5 is expected, the gap in alcohol consumption between men and women has been
6
7 progressively narrowing over the last years (34).
8

9
10 Admission related to cirrhosis was found to be inversely related to the presence of
11
12 multimorbidity, while CIRS was directly related to multimorbidity. These correlations
13
14 represent a counterproof of the validity of the classification applied for categorizing patients
15
16 as having either co- or multimorbidity. for example, a patient with cirrhosis and many other
17
18 randomly associated multiple chronic conditions (multimorbid) would be more likely to be
19
20 admitted to hospital due to one of these many multiple chronic conditions compared to a
21
22 patient with cirrhosis and its classical comorbidities, such as ascites, gastrointestinal
23
24 bleeding, or encephalopathy (comorbid). It is not surprising that, according to a recent expert
25
26 consensus, the evaluation of socioeconomic factors, educational status, and comorbid
27
28 psychiatric illness should all be taken into account by a multidisciplinary team in alcohol
29
30 cirrhosis patients (32). In fact, a low educational level was found to be common in our alcohol
31
32 cirrhosis patients, and interventions aimed at improving one's knowledge of the disease may
33
34 translate into a therapeutic advantage.
35
36
37
38
39
40
41

42 *Limitations*

43
44 We are aware that our study has some limitations that should be mentioned. The sample
45
46 size was rather small, especially for some cirrhosis aetiologies (e.g., autoimmune liver
47
48 disease), so we had to exclude these patients from our analysis. Hence, a wider
49
50 multivariable analysis could not be made. Even if our data should be considered as
51
52 preliminary in this field, a distinction between co- and multimorbidity could potentially aid
53
54 decision-making in cirrhotic patients, in whom a prioritisation of the clinical problems to be
55
56 solved is mandatory. Also, our data should be interpreted in the light of the specific setting
57
58 of enrolment, in which patients admitted are usually older than in others. Hence, our data
59
60

1
2
3 cannot be generalised to other settings, like that of the population level or the primary care.
4
5 Nevertheless, this study had some strengths, including a prospective collection of data, not
6
7 administrative based, but collected during the hospitalisation by a dedicated and qualified
8
9 staff of healthcare professionals who had been instructed before study commencement (20).
10
11
12
13

14 **CONCLUSION**

15
16 To conclude, we have performed the first study focusing on the distinction of comorbidity
17
18 and multimorbidity in a cohort of patients with a specific chronic condition. We found that
19
20 patients with alcoholic cirrhosis had a high comorbidity rate, while the other aetiologies -viral
21
22 and NAFLD- were mostly multimorbid due to ageing. How these characteristics may
23
24 translate into distinct and personalised clinical management should be further investigated.
25
26
27
28
29
30
31
32
33
34

35 **Data availability statement**

36
37 The full dataset of the study cannot be shared publicly at this stage, since the SMAC study
38
39 is still ongoing. Additional data can be shared upon request to the authors (please contact
40
41 Prof. Gino Roberto Corazza [gr.corazza@smatteo.pv.it]).
42
43
44
45
46

47 **Ethics approval and consent to participate**

48
49 The study protocol was approved by the local Ethics Committee (San Matteo Hospital
50
51 Foundation; 3 July 2017, Protocol number 2017/0019414). This research was performed in
52
53 accordance with the Declaration of Helsinki. Participants provided written informed consent.
54
55
56
57

58 **Competing interests**

59
60 The authors report no competing interests.

Funding

This research is part of a project for the study of clinical complexity (SMAC study) funded by San Matteo Hospital Foundation - Italian Ministry of Health (Progetto di Ricerca Corrente 2017; award number not applicable). The funding source had no role in the design, execution, analyses, and interpretation of the data.

Contributors

All authors participated in the drafting of the manuscript or critical revision of the manuscript for important intellectual content and provided approval of the final submitted version. Individual contributions are as follow: GRC designed and coordinated the study; MVL and AB drafted the manuscript; MVL, AB, GC, ASB, LP, GB, and ADS organised data collection conducted the study and/or enrolled patients; CK designed and performed statistical analysis, interpreted data, and revised the manuscript; GRC made the final critical revision for important intellectual content. All authors approved the final version of the paper.

Abbreviations: CIRS, Cumulative Illness Rating Scale; IQR, interquartile range; LOS, length of stay; MeSH, medical subject heading; NAFLD, non-alcoholic fatty liver disease; SBT, Short Blessed Test; SMAC, San MATteo Complexity.

References

1. Safford MM, Allison JJ, Kiefe CI. Patient complexity: more than comorbidity. the vector model of complexity. *J Gen Intern Med.* 2007;3:382-390.
2. Turner BJ, Cuttler L. The complexity of measuring clinical complexity. *Ann Intern Med.* 2011;155:851-852.

- 1
2
3 3. Corazza GR, Formagnana P, Lenti MV. Bringing complexity into clinical practice: An
4
5 internistic approach. *Eur J Intern Med.* 2019;61:9-14.
6
- 7
8 4. Goldenfeld N, Kadanoff LP. Simple lessons from complexity. *Science.* 1999;284:87-
9
10 89.
11
- 12
13 5. Plsek PE, Greenhalgh T. Complexity science: The challenge of complexity in health
14
15 care. *BMJ.* 2001;323:625-628.
16
- 17
18 6. Grant RW, Ashburner JM, Hong CS, Chang Y, Barry MJ, Atlas SJ. Defining patient
19
20 complexity from the primary care physician's perspective: a cohort study. *Ann Intern*
21
22 *Med.* 2011;155:797-804.
23
- 24
25 7. Hong CS, Atlas SJ, Ashburner JM, et al. Evaluating a model to predict primary care
26
27 physician-defined complexity in a large academic primary care practice-based
28
29 research network. *J Gen Intern Med.* 2015;30:1741-1747.
30
- 31
32 8. Tugwell P, Knottnerus JA. Multimorbidity and comorbidity are now separate MESH
33
34 headings. *J Clin Epidemiol.* 2019 [Epub ahead of print]
35
- 36
37 9. Nicholson K, Makovski TT, Griffith LE, Raina P, Stranges S, van den Akker M.
38
39 Multimorbidity and comorbidity revisited: refining the concepts for international health
40
41 research. *J Clin Epidemiol.* 2019;105:142-146.
42
- 43
44 10. Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. *Lancet.* 2014;383:1749-1761.
45
- 46
47 11. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of
48
49 survival in cirrhosis: a systematic review of 118 studies. *J Hepatol.* 2006;44:217-231.
50
- 51
52 12. Yang TW, Wang CC, Tsai MC, Wang YT, Tseng MH, Lin CC. Comorbidities and
53
54 outcome of alcoholic and non-alcoholic liver cirrhosis in Taiwan: a population-based
55
56 study. *Int J Environ Res Public Health.* 2020;17:2825.
57
- 58
59 13. Vaz J, Eriksson B, Strömberg U, Buchebner D, Midlöv P. Incidence, aetiology and
60
61 related comorbidities of cirrhosis: a Swedish population-based cohort study. *BMC*
Gastroenterol. 2020;20:84.

14. Jepsen P. Comorbidity in cirrhosis. *World J Gastroenterol*. 2014;20:7223-7230.
15. Jepsen P, Vilstrup H, Andersen PK, Sørensen HT. Socioeconomic status and survival of cirrhosis patients: a Danish nationwide cohort study. *BMC Gastroenterol*. 2009;9:35.
16. Roesch-Dietlen F, González-Santes M, Sánchez-Maza YJ, ET AL. Influence of socioeconomic and cultural factors in the aetiology of cirrhosis of the liver. *Rev Gastroenterol Mex*. 2021;86:28-35.
17. Vaz J, Strömberg U, Eriksson B, et al. Socioeconomic and marital status among liver cirrhosis patients and associations with mortality: a population-based cohort study in Sweden. *BMC Public Health* 2020. [Epub ahead of print]
18. Menche J, Sharma A, Kitsak M, et al. Disease networks. Uncovering disease-disease relationships through the incomplete interactome. *Science* 2015;347:1257601.
19. Corazza GR, Klersy C, Formagnana P, Lenti MV, Padula D; Consensus Panel. A consensus for the development of a vector model to assess clinical complexity. *Intern Emerg Med*. 2017;12:1313-1318.
20. Lenti MV, Klersy C, Brera AS, et al. Reproducibility in the assessment of the components of a clinical complexity index. *J Gen Intern Med*. 2019;34:2316-2318.
21. Lenti MV, Klersy C, Brera AS, et al. Clinical complexity and hospital admissions in the December holiday period. *PLoS One*. 2020;15:e0234112.
22. Lenti MV, Klersy C, Brera AS, et al. Aging underlies heterogeneity between comorbidity and multimorbidity frameworks. *Intern Emerg Med*. 2022 [Epub ahead of print]
23. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. *J Hepatol*. 2016;64:1388-402.

- 1
2
3 24. European Association for the Study of the Liver. EASL Clinical Practice Guidelines:
4
5 Management of alcohol-related liver disease. *J Hepatol*. 2018;69:154-181.
6
7
- 8 25. Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis.
9
10 *Lancet*. 2021 Oct 9;398:1359-1376.
11
- 12 26. Rolfson DB, Majumdar SR, Tsuyuki RT, Tahir A, Rockwood K. Validity and reliability
13
14 of the Edmonton Frail Scale. *Age Ageing*. 2006;35:526-9.
15
- 16 27. Mahoney FI, Barthel DW. Functional evaluation: the Barthel index. *Md State Med J*.
17
18 1965;14:61-5.
19
- 20 28. Ball LJ, Bisher GB, Birge SJ. A simple test of central processing speed: an extension
21
22 of the Short Blessed Test. *J Am Geriatr Soc*. 1999;47:1359-63.
23
- 24 29. De Vincentis A, Vespasiani-Gentilucci U, Costanzo L, et al; REPOSI Investigators.
25
26 The multifaceted spectrum of liver cirrhosis in older hospitalised patients: analysis of
27
28 the REPOSI registry. *Age Ageing*. 2021;50:498-504.
29
- 30 30. Dam Fialla A, Schaffalitzky de Muckadell OB, Touborg Lassen A. Incidence, aetiology
31
32 and mortality of cirrhosis: a population-based cohort study. *Scand J Gastroenterol*.
33
34 2012;47:702-709.
35
- 36 31. Sajja KC, Mohan DP, Rockey DC. Age and ethnicity in cirrhosis. *J Investig Med*.
37
38 2014;62:920-926.
39
- 40 32. Singal AK, Kwo P, Kwong A, et al. Research methodologies to address clinical unmet
41
42 needs and challenges in alcohol-associated liver disease. *Hepatology*. 2021 [Epub
43
44 ahead of print]
45
- 46 33. Wilsnack RW, Wilsnack SC, Kristjanson AF, Vogeltanz-Holm ND, Gmel G. Gender
47
48 and alcohol consumption: patterns from the multinational GENACIS project.
49
50 *Addiction*. 2009;104:1487-500.
51
- 52 34. Kezer CA, Simonetto DA, Shah VH. Sex differences in alcohol consumption and alcohol-
53
54 associated liver disease. *Mayo Clin Proc*. 2021;96:1006-1016.
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10 **Supplementary Figure legend**

11
12 **Supplementary Figure 1.** Calibration plot for the multivariable logistic model for multi/co-
13 morbidity. The red line of perfect calibration is included in the grey confidence band
14 indicating a good calibration of the model.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1. Baseline characteristics of the entire cohort of patients

	Cirrhotic patients	*Other patients	p value
Total number of patients, n (%)	172 (12.0)	1261 (88.0)	
Age, median (IQR)	79.0 (67.0-84.0)	80.0 (70.0-86.0)	0.275
Sex, n (%)			0.079
M	89 (51.7)	576 (45.7)	
F	83 (48.3)	685 (54.3)	
CIRS comorbidity index, median (IQR)	4.0 (3.0-5.0)	4.0 (2.0-5.0)	0.01
CIRS severity index, median (IQR)	1.85 (1.6-2.0)	1.77 (1.5-1.9)	<0.001
Co- multimorbidity, n (%)			0.003
None	0 (0)	57 (4.6)	
Comorbidity	35 (20.5)	251 (20.4)	
Multimorbidity	136 (79.5)	923 (75.0)	
BMI, median (IQR)	25.1 (21.5-29.2)	24.2 (21.3-27.7)	0.057
Edmonton Frail Scale >5, n (%)			0.724
No	50 (29.1)	377 (30.6)	
Yes	122 (70.9)	854 (69.4)	
Barthel index <60, n (%)			0.508
No	134 (77.9)	956 (77.6)	
Yes	38 (22.1)	276 (22.4)	
Short Blessed Test >9, n (%)			0.870
No	82 (47.9)	578 (47.1)	
Yes	89 (52.1)	649 (52.9)	
Income <1000 €/month, n (%)			0.935
No	89 (51.7)	641 (52.2)	
Yes	83 (48.3)	587 (47.8)	
Living alone, n (%)			0.439
No	137 (79.6)	944 (76.6)	
Yes	35 (20.4)	288 (23.4)	
Schooling <8 years, n (%)			0.032
No	69 (40.1)	590 (47.8)	
Yes	103 (59.9)	640 (52.0)	
Length of stay, median (IQR)	14.0 (9.0-20.0)	14.0 (10.0-23.0)	0.018

*This includes all the other patients enrolled in the SMAC study, with the exception of cirrhotic patients, as explained in the text. Abbreviations: BMI, Body Mass Index; CIRS, Cumulative Illness Rating Scale.

7 **Table 2.** Baseline characteristics of patients with cirrhosis according to the aetiology

	Alcohol (I)	Viral (II)	NAFLD (III)	p-value
Total number of patients, n (%)	33 (19.2)	79 (45.9)	60 (34.9)	/
Age, median (IQR)	65 (56-79)	81 (77-85)	78 (65-82)	< 0.001 0.007 (II vs III) < 0.001 (II vs I) 0.005 (III vs I)
Sex, n (%)				0.008
Male	25 (75.8)	37 (46.8)	27 (45.0)	
Female	8 (24.2)	42 (53.2)	33 (55.0)	
CIRS comorbidity index, median (IQR)	4.0 (3.0-5.0)	4.0 (3.0- 5.0)	4.0 (3.0- 6.0)	0.314
CIRS severity index, median (IQR)	1.85 (1.62- 1.92)	1.85 (1.62- 2.0)	1.85 (1.69- 2.15)	0.423
Co-multimorbidity, n (%)				0.015
Comorbidity	13 (39.4)	15 (19.0)	8 (13.3)	
Multimorbidity	20 (60.6)	64 (81.0)	52 (86.7)	
BMI, median (IQR)	23.4 (21.5- 29.4)	23.5 (20.5- 26.6)	27.1 (23.7- 31.8)	<0.001 <0.001 (II vs III) 0.11 (II vs I) 0.02 (III vs I)
Edmonton Frail Scale >5, n (%)				0.604
No	11 (33.3)	20 (25.3)	19 (31.7)	
Yes	22 (66.7)	59 (74.7)	41 (68.3)	
Barthel index <60				0.164
No	29 (87.9)	57 (72.1)	48 (80)	
Yes	4 (12.1)	22 (27.9)	12 (20)	
Income <1000 €/month, n (%)				0.523
No	14 (42.4)	43 (54.4)	32 (53.3)	
Yes	19 (57.6)	36 (45.6)	28 (46.7)	
Living alone, n (%)				0.219
No	26 (78.8)	59 (74.7)	52 (86.7)	
Yes	7 (21.2)	20 (25.3)	8 (13.3)	
Schooling <8 years, n (%)				0.282
No	12 (36.4)	28 (35.4)	29 (48.3)	
Yes	21 (63.6)	51 (64.6)	31 (51.7)	
Short Blessed Test >9, n (%)				0.102
No	20 (60.6)	31 (39.7)	31 (51.7)	
Yes	13 (39.4)	47 (60.3)	29 (48.3)	
Length of stay, median (IQR)	12.0 (8.0-19.0)	14.0 (9.0- 19.0)	14.0 (10.0-21.5)	0.423

8 Abbreviations: BMI, Body Mass Index; CIRS, Cumulative Illness Rating Scale.

9

10 **Table 3.** Multivariable analysis for factors associated with multimorbidity

11

	Odds ratio	95% CI	p-value
Sex			
Male	1.0 (reference)		
Female	1.63	0.64-4.14	0.308
Aetiology of cirrhosis			
			0.148
Viral	1.0 (reference)		
NAFLD	0.81	0.27-2.40	0.698
Alcohol	0.35	0.12-1.02	0.055
CIRS comorbidity index >3			
No	1.0 (reference)		
Yes	2.81	1.14-6.93	0.024
Barthel index <60			
No	1.0 (reference)		
Yes	2.84	0.61- 13.29	0.186
Admission related to cirrhosis			
No	1.0 (reference)		
Yes	0.19	0.07-0.54	0.002

12 Model Chi² 32.23, p-value<0.001; area under the ROC curve=0.79; calibration belt p=0.709, plot within 95%
 13 Cl.


1
2 14 Abbreviations: Cumulative Illness Rating Scale, CIRS; NAFLD, non-alcoholic fatty liver disease.
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

For peer review only

Supplementary Table 1. Univariable analysis of the candidate variables.

	Comorbidity, n (%)	Multimorbidity, n (%)	p-value
Sex			0.027
Male	29 (29.0)	71 (71.0)	
Female	14 (16.1)	73 (83.9)	
Aetiology of cirrhosis			0.015
Viral	15 (19.0)	64 (81.0)	
NAFLD	8 (13.3)	52 (86.7)	
Alcohol	13 (39.4)	20 (60.6)	
CIRS comorbidity index >3			0.066
No	22 (29.3)	53 (70.7)	
Yes	21 (18.8)	91 (81.2)	
Barthel index <60			0.019
No	39 (26.5)	108 (73.5)	
Yes	4 (10.0)	36 (90.0)	
Admission related to cirrhosis			<0.001
No	24 (16.1)	125 (83.9)	
Yes	18 (56.3)	14 (43.7)	

Supplementary Figure 1



STROBE Statement—checklist of items that should be included in reports of observational studies
 Paper: Determinants of clinical complexity in hospitalized cirrhotic patients by Lenti MV et al.

	Item No.	Recommendation	Page No.
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1-2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	3-4
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4-5
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	4-6
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4-6
Bias	9	Describe any efforts to address potential sources of bias	4-6
Study size	10	Explain how the study size was arrived at	6

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Continued on next page

For peer review only

Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	6
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	6
		(b) Describe any methods used to examine subgroups and interactions	6
		(c) Explain how missing data were addressed	6
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed	NA
		<i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	NA
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	6-8
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6-8
		(b) Indicate number of participants with missing data for each variable of interest	6-8
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	6-8
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	6-8
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6-8
		(b) Report category boundaries when continuous variables were categorized	6-8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	NA
Discussion			
Key results	18	Summarise key results with reference to study objectives	8-10
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	8-10
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	8-10
Generalisability	21	Discuss the generalisability (external validity) of the study results	8-10
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	11

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.